Hypermobile Ehlers-Danlos Syndrome

Genetic MONDO:0007523 Pathograph 7 Show in embeddings browser Ehlers-Danlos Syndrome Connective Tissue Disorder

Hypermobile Ehlers-Danlos syndrome is a clinically defined Ehlers-Danlos subtype characterized by generalized joint hypermobility, joint instability, recurrent subluxations or dislocations, chronic pain, soft or hyperextensible skin, easy bruising, fatigue, autonomic and gastrointestinal symptoms, and other multisystem features. Unlike the monogenic EDS subtypes, no validated causal gene or biomarker has been identified, so diagnosis is made clinically using the 2017 international criteria.

Ask OpenScientist

Ask a research question about Hypermobile Ehlers-Danlos Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
3
Pathophys.
21
Phenotypes
7
Gaps
7
Pathograph
2
Medical Actions
3
Datasets
3
References
2
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance pattern HP:0000006
Familial hEDS often appears autosomal dominant, but no validated causal gene or variant class is available for diagnostic testing.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Hypermobile EDS is inherited in an autosomal dominant manner with variable expression of signs and variable severity of symptoms among affected family members."
GeneReviews describes the observed familial inheritance pattern while separately noting that no causal etiology is known.
?

Discussions and Knowledge Gaps

7
Is hEDS a locus-heterogeneous Mendelian disorder, a common-variant complex trait, or a composite of both?
KNOWLEDGE GAP OPEN gap_heds_causal_architecture
Attached to
pathophysiology#Unresolved ECM remodeling and joint-stability failure inheritance#Autosomal dominant inheritance pattern
The entry records autosomal dominant transmission, but no causal gene has been validated. Exome sequencing of diagnostically unresolved EDS found candidate loci without genome-wide significance, a GWAS meta-analysis found common-variant contributions, and a KLK15 missense variant segregated in two families with a supporting knock-in mouse. These three results are compatible with very different disease architectures, and the choice between them determines whether diagnostic sequencing is even the right instrument.
Proposed experiments
Joint rare-variant and common-variant architecture partition
statistical genetics architecture partition Relation: this experiment is of type this experiment type This experiment is of type statistical genetics architecture partition.
exp_heds_joint_architecture_partition
Partition hEDS liability across rare and common variation in a single analysis rather than in separate studies. Combine the HEDGE whole-genome cohort with published GWAS summary statistics to estimate SNP-based heritability, gene-level rare-variant burden, and the fraction of familial recurrence each explains. Include an explicit replication arm for KLK15 and the wider kallikrein family in unrelated probands.
Decision criterion
Whether rare-variant burden or common-variant polygenic score explains the larger share of liability, and whether kallikrein-family burden replicates outside the discovery cohort. A monogenic or oligogenic architecture is indicated if replicated rare-variant burden dominates and segregates in families; a complex-trait architecture if SNP-based heritability dominates and no gene reaches exome-wide significance, which would also remove the expectation that a single validated causal gene is the endpoint of hEDS genetics.
Would support
inheritance#Autosomal dominant inheritance pattern
Would refute
inheritance#Autosomal dominant inheritance pattern
Show evidence (5 references)
PMID:37813462 SUPPORT Human Clinical
"Genetic burden analysis revealed a number of novel loci, although none reached the threshold for genome-wide significance."
Exome sequencing of unresolved EDS patients failed to identify a significant locus, which is the primary evidence that hEDS is not a simple monogenic disorder.
PMID:41001447 SUPPORT Human Clinical
"In contrast to other EDS subtypes with defined genetic causes, the molecular basis of hEDS has remained elusive."
The GWAS meta-analysis states the unresolved molecular basis that motivates this gap, and supplies the common-variant arm of the competing hypotheses.
PMID:38947032 SUPPORT Human Clinical
"A missense variant in Kallikrein-15 (KLK15 p. Gly226Asp), segregated with disease in two families"
The human-genetic arm of the monogenic hypothesis: KLK15 segregates with disease in two families. Partial rather than full support because the finding is unreplicated outside the discovery cohort.
+ 2 more references
Is the 2017 criteria-based split between hEDS and hypermobility spectrum disorder biologically real, or an artifact of a threshold-based checklist?
CONTROVERSY OPEN gap_heds_hsd_boundary
Attached to
pathophysiology#Unresolved ECM remodeling and joint-stability failure pathophysiology#Myofibroblast-like fibroblast transition
Two independent molecular datasets from the same group point the same way: dermal fibroblast RNA-seq across 20 hEDS and 20 HSD patients found a shared cellular phenotype, and plasma ECM-fragmentation profiling found a shared fibronectin and collagen-I signature. If no molecular boundary exists, the dismech decision to keep separate hEDS and HSD framing needs an explicit justification, and cohort assembly for every other hEDS question is affected.
Proposed experiments
Blinded molecular classifier for the hEDS/HSD boundary
supervised classification of transcriptomic profiles Relation: this experiment is of type this experiment type This experiment is of type supervised classification of transcriptomic profiles.
exp_heds_hsd_blinded_molecular_classifier
Train a classifier on GSE218012 dermal fibroblast RNA-seq to separate hEDS from HSD, with healthy donors as a positive-control contrast, using nested cross-validation and label permutation to establish the null. Repeat on plasma ECM-fragment profiles from an independent cohort.
Decision criterion
Whether hEDS-versus-HSD classification accuracy exceeds the permuted null, given that the same pipeline separates patients from healthy donors. A real biological boundary is indicated if hEDS and HSD separate above the null; a single-entity model if the two are inseparable while both separate from controls, which would mean the 2017 criteria threshold does not track a molecular distinction and that these nodes describe one shared substrate rather than an hEDS-specific one.
Would support
pathophysiology#Unresolved ECM remodeling and joint-stability failure pathophysiology#Myofibroblast-like fibroblast transition
Would refute
pathophysiology#Unresolved ECM remodeling and joint-stability failure pathophysiology#Myofibroblast-like fibroblast transition
Show evidence (2 references)
PMID:39225014 SUPPORT Human Clinical
"supporting their classification as a single disorder and prompting reconsideration of the hEDS criteria"
The plasma biomarker study explicitly argues that hEDS and HSD should be treated as one entity, which is the controversy recorded here.
PMID:36552803 SUPPORT In Vitro
"We demonstrated that both cell types show a common cellular trait, i.e., generalized extracellular matrix (ECM) disarray, myofibroblast differentiation, and dysregulated gene expression."
Independent transcriptomic evidence that hEDS and HSD fibroblasts share the same cellular phenotype.
What is the minimum sufficient genetic workup before criterion 3 of the 2017 criteria (exclusion of alternative diagnoses) can be considered satisfied?
KNOWLEDGE GAP OPEN gap_heds_criterion3_exclusion_boundary
Attached to
pathophysiology#Unresolved ECM remodeling and joint-stability failure
hEDS is a diagnosis of exclusion, but the exclusion set is undefined. In a single-center series, a quarter of patients who already met all three 2017 criteria were found on genetic testing to have an alternative or additional diagnosis with different management. Without a specified panel, criterion 3 is unfalsifiable and cohort purity varies by center, which contaminates every downstream hEDS study including the genetic ones.
Proposed experiments
Diagnostic-yield curve for a defined hEDS exclusion panel
retrospective diagnostic yield analysis Relation: this experiment is of type this experiment type This experiment is of type retrospective diagnostic yield analysis.
exp_heds_exclusion_panel_yield_curve
Assemble a candidate exclusion gene set from the EDS, Loeys-Dietz, heritable thoracic aortic disease, and EDS-mimicking Mendelian disorder panels, annotated with ClinGen gene-disease validity and dosage sensitivity. Apply it retrospectively to consecutive criteria-positive hEDS cohorts and plot reclassification yield against panel size to find where the curve flattens.
Decision criterion
The panel size at which incremental reclassification yield falls below a pre-specified threshold. A bounded minimum panel that makes criterion 3 operational is indicated if the curve flattens; a high sustained reclassification yield would instead mean criteria-positive cohorts are substantially contaminated by alternative diagnoses, undermining the cohort basis on which this node's mechanism evidence rests.
Would support
pathophysiology#Unresolved ECM remodeling and joint-stability failure
Would refute
pathophysiology#Unresolved ECM remodeling and joint-stability failure
Show evidence (1 reference)
PMID:40428350 SUPPORT Human Clinical
"Genetic testing identified an alternative or additional diagnosis in 47 of these individuals (26.4%), with clinical implications requiring distinct management strategies."
Quantifies how often criteria-positive hEDS patients carry an alternative diagnosis, establishing that criterion 3 is currently under-enforced.
What mechanistic chain connects a connective-tissue defect to the small-fiber neuropathy, orthostatic cerebral hypoperfusion, and POTS seen in most hEDS patients?
KNOWLEDGE GAP OPEN gap_heds_dysautonomia_mechanism
Attached to
pathophysiology#Unresolved ECM remodeling and joint-stability failure phenotypes#Orthostatic tachycardia phenotypes#Peripheral neuropathy phenotypes#Gastrointestinal dysmotility
Deep phenotyping shows the neurologic and autonomic burden is near-universal rather than incidental, yet gastroenterology guidance states plainly that the biological mechanisms behind these associations are not established. The dismech entry currently carries orthostatic tachycardia, peripheral neuropathy, and GI dysmotility as phenotypes with no causal edge from any pathophysiology node, which faithfully reflects the state of knowledge and marks exactly where the model is incomplete.
Proposed experiments
Genotype-anchored small-fiber neuropathy stratification
genotype-stratified deep phenotyping study Relation: this experiment is of type this experiment type This experiment is of type genotype-stratified deep phenotyping study.
exp_heds_neuroimmune_locus_to_nerve_bridge
Stratify a deeply phenotyped hEDS cohort with skin biopsy intraepidermal nerve fiber density, autonomic function testing, and transcranial Doppler cerebral blood flow by genotype at the GWAS-implicated regulatory locus, using GTEx tibial nerve as the eQTL reference tissue. Test whether risk allele carriers show greater fiber loss or cerebral hypoperfusion than non-carriers with equivalent joint phenotypes.
Decision criterion
Whether neuropathic and cerebrovascular measures differ by genotype at the candidate locus after adjustment for joint-phenotype severity. A genotype effect surviving that adjustment indicates a neuroimmune arm partly independent of the ECM arm, and would require a pathophysiology node this entry does not yet have; no genotype effect is consistent with a purely mechanical model in which the autonomic and neuropathic phenotypes are secondary to connective-tissue laxity alone.
Would support
phenotypes#Orthostatic tachycardia phenotypes#Peripheral neuropathy
Would refute
pathophysiology#Unresolved ECM remodeling and joint-stability failure
Show evidence (3 references)
PMID:40387691 SUPPORT Other
"while theoretical explanations exist, experimental evidence of the biological mechanisms that explain relationships is limited and evolving"
A society expert review stating directly that the mechanism behind the hEDS/POTS/MCAS association is unestablished.
PMID:40843452 SUPPORT Human Clinical
"Small fiber neuropathy using structural criteria was detected in 64%, and using combined structural and functional criteria in 82%."
Establishes that small-fiber neuropathy is a majority finding in hEDS, making its absent mechanistic explanation a first-order gap.
PMID:40843452 SUPPORT Human Clinical
"Orthostatic cerebral blood flow velocity was reduced in 79% of hEDS and correlated with orthostatic dizziness."
Provides the cerebrovascular readout that a mechanistic model would need to explain.
Is fascia, rather than dermis, the primary affected tissue in hEDS, and is the dermal fibroblast phenotype a proxy for it?
OPEN QUESTION OPEN gap_heds_fascia_versus_dermis_substrate
Attached to
pathophysiology#Myofibroblast-like fibroblast transition pathophysiology#Joint instability and chronic pain
Every molecular dataset in this entry is derived from dermal fibroblasts, because skin is what is easy to biopsy. A fascia-centered model proposes that the clinically relevant substrate is deep fascia, where thickness, interfascial gliding, and stiffness abnormalities have been reported. If correct, the dermal fibroblast phenotype the pathophysiology nodes rest on is an accessible surrogate rather than the affected tissue, and no public fascia-specific omics dataset exists to test this.
Proposed experiments
Paired fascia and dermis transcriptomic comparison
paired-tissue transcriptomic comparison Relation: this experiment is of type this experiment type This experiment is of type paired-tissue transcriptomic comparison.
exp_heds_paired_fascia_dermis_transcriptome
Collect paired deep fascia and dermis biopsies from the same hEDS patients and matched controls, with ultrasound measurement of fascial thickness and interfascial gliding at the biopsy site. Compare the ECM-remodeling and myofibroblast signatures between tissues within each patient, so that tissue effect is estimated independently of between-patient variation.
Decision criterion
Whether the disease signature is stronger in fascia than in paired dermis from the same individual, and whether it tracks the imaging measures. Concordance between the two tissues validates dermal fibroblasts as a surrogate and leaves these nodes standing; a signature confined to or much stronger in fascia indicates a fascia-primary model, and would mean the dermal fibroblast findings cannot be read directly as the tissue-level mechanism of joint instability.
Would support
pathophysiology#Myofibroblast-like fibroblast transition pathophysiology#Joint instability and chronic pain
Would refute
pathophysiology#Myofibroblast-like fibroblast transition
Show evidence (2 references)
PMID:40565051 SUPPORT Other
"By reframing hEDS and HSD as disorders of pathological fascial remodeling, this review offers an integrated model that connects molecular mechanisms with clinical expression."
States the competing tissue-level model that this open question is about.
PMID:40565051 SUPPORT Other
"It underscores the urgent need for multidisciplinary research to define diagnostic biomarkers, clarify therapeutic targets"
The review itself frames these as unresolved research needs rather than established findings.
Why is hEDS diagnosed in women several times more often than in men despite apparently autosomal dominant transmission?
KNOWLEDGE GAP OPEN gap_heds_sex_ratio
Attached to
inheritance#Autosomal dominant inheritance pattern
Clinic series report female-to-male ratios of roughly 7:1 for hEDS and higher still for HSD, which is irreconcilable with autosomal dominant inheritance unless sex modifies penetrance, expressivity, or ascertainment. The competing explanations (hormonal modulation of connective tissue, sex differences in pain reporting, referral and diagnostic bias) have different consequences: one is disease biology that belongs in the pathograph, the others are study design artifacts that would bias every hEDS cohort assembled to date.
Proposed experiments
Ascertainment-controlled sex ratio decomposition
ascertainment bias decomposition Relation: this experiment is of type this experiment type This experiment is of type ascertainment bias decomposition.
exp_heds_sex_ratio_ascertainment_decomposition
Compare the hEDS sex ratio between referral-based clinic cohorts and population-based sampling frames such as biobank or national registry cohorts ascertained on diagnosis codes rather than specialist referral. Within families, compare penetrance in male versus female first-degree relatives of affected probands, which holds genotype risk approximately constant across sexes.
Decision criterion
Whether the sex ratio persists in population-based and within-family sampling after removing referral-based ascertainment. Persistence within families indicates sex-modified penetrance as real disease biology, which would qualify the plain autosomal dominant model recorded here; a ratio collapsing toward 1:1 under population sampling indicates a purely ascertainment-driven explanation and leaves the inheritance model intact.
Would support
inheritance#Autosomal dominant inheritance pattern
Would refute
inheritance#Autosomal dominant inheritance pattern
Show evidence (1 reference)
PMID:41993759 SUPPORT Human Clinical
"Although hEDS and HSD are autosomal-dominant conditions and would be expected to display a 1:1 sex ratio, studies report higher prevalence in women."
States the inheritance-versus-observation contradiction that defines this gap.
Is the alpha-v-beta-3/ILK/Snail1 myofibroblast transition a causal driver of extracellular matrix failure in hEDS, a passenger of the disease state, or a mechanotransduction artifact of culture on rigid plastic?
KNOWLEDGE GAP OPEN gap_heds_myofibroblast_causal_dependency
Attached to
pathophysiology#Myofibroblast-like fibroblast transition pathophysiology#Unresolved ECM remodeling and joint-stability failure
The myofibroblast-like transition is the most mechanistically detailed node in this entry, but every observation supporting it comes from patient fibroblasts grown on tissue-culture plastic, and the node's own description already concedes it is model evidence rather than a validated biomarker. Substrate rigidity is an independent and sufficient inducer of myofibroblast differentiation in disease fibroblasts, so the reported hEDS phenotype is confounded by the culture format at the point of measurement. Three outcomes are live: the transition is a causal dependency of ECM failure, a passenger that tracks disease without driving it, or a stiffness artifact that a soft substrate abolishes in patient and control cells alike. The node currently carries no downstream causal edges, which is the honest reflection of that uncertainty; only the first outcome would justify drawing one, and only the first makes the axis a therapeutic target.
Proposed experiments
Stiffness-controlled perturbation screen of the myofibroblast transition
high-content perturbation screen Relation: this experiment is of type this experiment type This experiment is of type high-content perturbation screen.
exp_heds_myofibroblast_stiffness_controlled_perturbation
Culture a panel of hEDS, HSD, and control dermal fibroblasts across a substrate-stiffness series spanning soft matrix and rigid tissue-culture plastic, crossed with a bounded perturbation set targeting the proposed axis (alpha-v-beta-3 integrin blockade, ILK inhibition, SNAI1 knockdown, TGF-beta pathway modulation, MMP9 inhibition). Score alpha-smooth muscle actin stress-fiber organization, fibronectin matrix assembly, MMP9 secretion, and migration by high-content imaging, with the perturbation set chosen from the differentially expressed genes in GSE218012. The stiffness arm is the control the existing literature lacks, and the plate-based readouts make this the one gap in this entry with a protocol an autonomous laboratory could compile and run.
Model systems
Patient-derived dermal fibroblast panel on defined-stiffness substrates
Primary hEDS, HSD, and control dermal fibroblasts cultured on hydrogels of controlled elastic modulus alongside conventional rigid plastic.
PRIMARY CELL CULTURE
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Decision criterion
Whether the hEDS-versus-control difference in myofibroblast conversion and matrix assembly survives on soft substrate, and whether perturbing the alpha-v-beta-3/ILK/Snail1 axis rescues matrix assembly rather than only reducing the alpha-smooth muscle actin marker. A causal dependency is indicated if axis perturbation restores matrix assembly and the patient-control difference persists on soft substrate; a passenger role if perturbation removes the marker without restoring matrix assembly; and a rigid-culture mechanotransduction artifact rather than hEDS biology if the patient-control difference disappears on soft substrate.
Would support
pathophysiology#Myofibroblast-like fibroblast transition
Would refute
pathophysiology#Myofibroblast-like fibroblast transition
Show evidence (4 references)
PMID:29587413 SUPPORT In Vitro
"In hEDS and HSD cells, the αvβ3 integrin was shown to be involved in the fibroblast-to-myofibroblast transition"
Establishes the specific signaling axis this gap proposes to test as a causal dependency.
PMID:31409039 SUPPORT In Vitro
"Our in vitro studies confirmed the phenotypic conversion of hEDS/HSD fibroblasts into migrating myofibroblast-like cells"
Confirms the observation is reproducible in vitro, which is what makes the culture-format confound worth resolving rather than dismissing.
PMID:40343813 SUPPORT In Vitro
"culture in soft microenvironments (as spheroids or on soft collagen-coated substrate) redirects myofibroblasts to a lipofibroblast-like phenotype"
Demonstrates in disease-derived fibroblasts that substrate stiffness alone controls myofibroblast identity, establishing the confound that motivates the stiffness-controlled arm of the proposed experiment.
+ 1 more reference
⚙

Pathophysiology

3
Unresolved ECM remodeling and joint-stability failure
hEDS lacks a validated monogenic cause. Current model evidence points to abnormal collagen/fibronectin extracellular-matrix organization, excessive matrix remodeling, and pro-inflammatory myofibroblast-like fibroblast changes as candidate mechanisms that may contribute to joint instability, chronic pain, fatigue, and multisystem symptoms.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Joint instability and chronic pain Weak or dysregulated connective-tissue support permits recurrent subluxations, dislocations, soft-tissue injury, and chronic pain.
Myofibroblast-like fibroblast transition In vitro hEDS/HSD fibroblasts show a candidate pro-inflammatory myofibroblast-like phenotype mediated through alpha-v-beta-3 integrin/ILK/Snail1 signaling.
Show evidence (3 references)
PMID:20301456 SUPPORT Human Clinical
"Currently, no underlying genetic, epigenetic, or metabolomic etiology has been identified for hEDS."
GeneReviews supports keeping the primary etiology unresolved.
PMID:31409039 SUPPORT Other
"skin fibroblasts show a disorganization of the ECM like that observed in cells derived from the other EDS types."
This model-based review supports ECM disorganization as a candidate mechanism while not establishing a causal gene.
PMID:31409039 SUPPORT Other
"hEDS/HSD, cEDS, and vEDS fibroblasts exhibit a marked disorganization of collagen and fibronectin ECM and their specific α2β1 and α5β1 integrin receptors and showed the preferential expression of the αvβ3 integrin"
Patient-fibroblast studies point to loss of the canonical collagen and fibronectin integrin receptors with preferential αvβ3 integrin recruitment as a candidate hEDS matrix-remodeling mechanism.
Joint instability and chronic pain
Dysregulated connective-tissue support and recurrent soft-tissue injury manifest clinically as subluxations, dislocations, acute injury pain, and chronic pain.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Joint hypermobility Joint-stability failure in hEDS presents clinically as generalized joint hypermobility.
Joint dislocation Joint instability predisposes to recurrent subluxations and dislocations.
Chronic pain Repeated joint and soft-tissue injury contributes to chronic pain beyond acute injury pain.
Arthralgia Joint instability and repeated injury produce joint pain.
Show evidence (2 references)
PMID:20301456 SUPPORT Human Clinical
"Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
GeneReviews supports recurrent instability and soft-tissue injury as the clinical downstream consequence.
PMID:20301456 SUPPORT Human Clinical
"Chronic pain, distinct from that associated with acute injury, is common and often neuropathic in nature."
GeneReviews supports chronic pain as part of this downstream clinical branch.
Myofibroblast-like fibroblast transition
hEDS/HSD patient fibroblasts can acquire a migrating myofibroblast-like phenotype with alpha-smooth muscle actin stress fibers, cadherin-11, MMP9, and inflammatory mediator changes through alpha-v-beta-3 integrin/ILK/Snail1 signaling. This remains model evidence rather than a validated diagnostic biomarker.
dermal fibroblast CL:0002620 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dermal fibroblast, annotated with skin fibroblast (CL:0002620). CL:0002620 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (3 references)
PMID:31409039 SUPPORT In Vitro
"Our in vitro studies confirmed the phenotypic conversion of hEDS/HSD fibroblasts into migrating myofibroblast-like cells"
This review summarizes patient-cell evidence for a candidate myofibroblast-like transition in hEDS/HSD.
PMID:29587413 SUPPORT In Vitro
"In hEDS and HSD cells, the αvβ3 integrin was shown to be involved in the fibroblast-to-myofibroblast transition by a transduction pathway involving ILK that signals to the transcription factor Snail1"
The primary cell-model paper supports the integrin/ILK/Snail1 branch.
PMID:29587413 SUPPORT In Vitro
"hEDS and HSD cells exhibit a peculiar in vitro myofibroblast-like phenotype characterized by organization of the α-smooth muscle actin (α-SMA) cytoskeleton, expression of the cadherin-11, and enhanced migratory capability, probably because they synthesize high levels of MMP9, a collagenase also..."
Patient fibroblasts show the α-SMA/cadherin-11 myofibroblast markers and high MMP9 collagenase, providing a candidate ECM-degrading mechanism that generates fibronectin fragments driving the transition.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hypermobile Ehlers-Danlos Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Blood 1
Easy bruising Bruising susceptibility HP:0000978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Easy bruising, annotated with Bruising susceptibility (HP:0000978). HP:0000978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"pain, soft and hyperextensible skin with atrophic scars and easy bruising"
GeneReviews lists easy bruising among hEDS clinical features.
Cardiovascular 2
Mitral valve prolapse FREQUENT HP:0001634 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral valve prolapse (HP:0001634). HP:0001634 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:285 SUPPORT Human Clinical
"HP:0001634 | Mitral valve prolapse | Frequent (79-30%)"
Orphanet lists mitral valve prolapse as frequent.
PMID:20301456 SUPPORT Human Clinical
"mitral valve prolapse, and aortic root dilatation."
GeneReviews lists mitral valve prolapse among hEDS clinical characteristics.
Aortic root dilatation Aortic root aneurysm HP:0002616 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic root dilatation, annotated with Aortic root aneurysm (HP:0002616). HP:0002616 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Mitral valve prolapse and aortic root dilatation, when present, are typically of a mild degree with no increased risk of cardiac complications."
GeneReviews lists aortic root dilatation as a hEDS cardiovascular feature and notes that it is typically mild.
Integument 3
Hyperextensible skin HP:0000974 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperextensible skin (HP:0000974). HP:0000974 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"pain, soft and hyperextensible skin with atrophic scars and easy bruising"
GeneReviews lists soft and hyperextensible skin among hEDS features.
Acrocyanosis VERY_FREQUENT HP:0001063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acrocyanosis (HP:0001063). HP:0001063 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:285 SUPPORT Human Clinical
"HP:0001063 | Acrocyanosis | Very frequent (99-80%)"
Orphanet lists acrocyanosis as very frequent.
Atrophic scars HP:0001075 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atrophic scars (HP:0001075). HP:0001075 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"soft and hyperextensible skin with atrophic scars and easy bruising"
GeneReviews lists atrophic scars among the cutaneous features of hEDS.
Musculoskeletal 2
Joint hypermobility HP:0001382 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hypermobility (HP:0001382). HP:0001382 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility"
GeneReviews identifies generalized joint hypermobility as a core hEDS feature.
Joint dislocation HP:0001373 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint dislocation (HP:0001373). HP:0001373 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
GeneReviews directly supports recurrent subluxations and dislocations.
Nervous System 5
Orthostatic tachycardia HP:0012173 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Orthostatic tachycardia (HP:0012173). HP:0012173 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
GeneReviews lists cardiovascular autonomic dysfunction among common hEDS manifestations; orthostatic tachycardia captures the common POTS-like autonomic phenotype highlighted by hEDS reviews.
Migraine HP:0002076 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Migraine (HP:0002076). HP:0002076 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"sleep disorders including apnea, migraine"
GeneReviews includes migraine among common hEDS manifestations.
Sleep disturbance HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"sleep disorders including apnea, migraine"
GeneReviews includes sleep disorders among common hEDS manifestations.
Peripheral neuropathy HP:0009830 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral neuropathy (HP:0009830). HP:0009830 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"entrapment and peripheral neuropathies"
GeneReviews lists entrapment and peripheral neuropathies among common hEDS manifestations.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"anxiety disorders, and urogynecologic disorders are common."
GeneReviews lists anxiety disorders among common hEDS manifestations.
Constitutional 4
Chronic pain HP:0012532 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic pain (HP:0012532). HP:0012532 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Chronic pain, distinct from that associated with acute injury, is common and often neuropathic in nature."
GeneReviews directly supports chronic pain in hEDS.
Fatigue HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
GeneReviews lists chronic fatigue among common hEDS manifestations.
Arthralgia VERY_FREQUENT HP:0002829 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arthralgia (HP:0002829). HP:0002829 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:285 SUPPORT Human Clinical
"HP:0002829 | Arthralgia | Very frequent (99-80%)"
Orphanet lists arthralgia as very frequent.
Myalgia VERY_FREQUENT HP:0003326 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myalgia (HP:0003326). HP:0003326 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:285 SUPPORT Human Clinical
"HP:0003326 | Myalgia | Very frequent (99-80%)"
Orphanet lists myalgia as very frequent.
Other 4
Soft skin FREQUENT HP:0000977 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Soft skin (HP:0000977). HP:0000977 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:285 SUPPORT Human Clinical
"HP:0000977 | Soft skin | Frequent (79-30%)"
Orphanet lists soft skin as a frequent hEDS phenotype.
PMID:20301456 SUPPORT Human Clinical
"pain, soft and hyperextensible skin with atrophic scars and easy bruising"
GeneReviews lists soft skin among hEDS clinical features.
Dental crowding FREQUENT HP:0000678 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dental crowding (HP:0000678). HP:0000678 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:285 SUPPORT Human Clinical
"HP:0000678 | Dental crowding | Frequent (79-30%)"
Orphanet lists dental crowding as frequent.
PMID:20301456 SUPPORT Human Clinical
"dental crowding, abdominal hernias, pelvic organ prolapse"
GeneReviews lists dental crowding among hEDS clinical characteristics.
Gastrointestinal dysmotility OCCASIONAL HP:0002579 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gastrointestinal dysmotility (HP:0002579). HP:0002579 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:285 SUPPORT Human Clinical
"HP:0002579 | Gastrointestinal dysmotility | Occasional (29-5%)"
Orphanet lists gastrointestinal dysmotility as occasional.
PMID:20301456 SUPPORT Human Clinical
"Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
GeneReviews lists functional bowel disorders among common hEDS manifestations.
Pelvic organ prolapse HP:0031607 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pelvic organ prolapse (HP:0031607). HP:0031607 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"abdominal hernias, pelvic organ prolapse, marfanoid body habitus"
GeneReviews lists pelvic organ prolapse among hEDS clinical characteristics.
💊

Medical Actions

2
Exercise-based physical therapy and joint stabilization
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
hEDS care is symptom-directed and includes progressive strengthening, proprioceptive exercise, braces or splints, assistive devices, and avoidance of activities that provoke subluxation or pain.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Tailored treatment with exercise to increase core and extremity muscle strength and tone, proprioception, and joint stability"
GeneReviews supports exercise-based treatment aimed at strength, proprioception, and stability.
Multisystem symptom management
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Pain, autonomic, gastrointestinal, oral, neurologic, sleep, psychiatric, and urogynecologic manifestations are managed with individualized supportive care and surveillance.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Surveillance: Assess for joint manifestations, pain, disability, bleeding issues, functional bowel disorders, autonomic dysfunction"
GeneReviews supports periodic multisystem assessment and symptom-directed care.
📈

Progression

2
Lifelong variable multisystem disorder
Age: Childhood through adulthood
hEDS is not modeled as a single fatal degenerative sequence; instead, affected individuals have variable lifelong joint instability, pain, fatigue, soft-tissue injury, and multisystem manifestations.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"variable expression of signs and variable severity of symptoms among affected family members."
GeneReviews supports variable expression and severity rather than a fixed monogenic progression sequence.
Recurrent instability and chronic symptom burden
Age: Any age after onset
Recurrent subluxations or dislocations and soft-tissue injuries can lead to chronic pain, fatigue, functional impairment, and repeated supportive care needs.
Show evidence (1 reference)
PMID:20301456 SUPPORT Human Clinical
"Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
This supports recurrent injury/instability as a recurring clinical course feature in hEDS.
📊

Related Datasets

3
Whole-transcriptome analysis of dermal fibroblasts from patients with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders supports their categorization as a single clinical entity with a contribution of inflammatory pathways geo:GSE218012
Amplicon-based RNA-seq of cultured dermal fibroblasts from 20 hEDS patients, 20 HSD patients, and 40 healthy donors. The largest public hEDS omics resource, and the only one powered to test whether a transcriptional boundary separates hEDS from HSD. Note that sample_count (200) is the GEO GSM sample count and is distinct from the 80 donors; the GEO series lists biological and technical replicates per donor as separate samples.
human BULK RNA SEQ n=200 GPL23934 Ion Torrent S5 (Homo sapiens)
dermal fibroblast CL:0002620 Cell Ontology (CL) Relation: this dataset samples this sample type This dataset samples dermal fibroblast, annotated with skin fibroblast (CL:0002620). CL:0002620 is a sample type from the Cell Ontology.
Conditions: Hypermobile Ehlers-Danlos syndrome Hypermobility spectrum disorder Healthy donor control
PMID:36552803
Show evidence (1 reference)
PMID:36552803 SUPPORT In Vitro
"We demonstrated that both cell types show a common cellular trait, i.e., generalized extracellular matrix (ECM) disarray, myofibroblast differentiation, and dysregulated gene expression."
The associated publication reports that hEDS and HSD fibroblasts share the ECM-disarray and myofibroblast phenotype, which is the claim this dataset is cited to support.
Microarray expression data from five Ehlers-Danlos Syndrome Hypermobility type/Joint Hypermobility Syndrome (EDS-HT/JHS) patients' skin fibroblasts geo:GSE77753
Affymetrix Gene 1.0 ST transcriptome profiling of skin fibroblasts from five JHS/EDS-HT (legacy hEDS nomenclature) patients versus six healthy individuals. Small but independent of the later RNA-seq cohort, so usable as a replication set.
human MICROARRAY n=11 Affymetrix Human Gene 1.0 ST Array
dermal fibroblast CL:0002620 Cell Ontology (CL) Relation: this dataset samples this sample type This dataset samples dermal fibroblast, annotated with skin fibroblast (CL:0002620). CL:0002620 is a sample type from the Cell Ontology.
Conditions: Joint hypermobility syndrome / Ehlers-Danlos syndrome hypermobility type Healthy control
PMID:27518164
Show evidence (1 reference)
PMID:27518164 SUPPORT In Vitro
"Transcriptome analysis indicated perturbation of different signaling cascades that are required for homeostatic regulation either during development or in adult tissues"
The associated publication defines the transcriptomic content of this dataset.
microRNA expression profile from five Ehlers-Danlos Syndrome Hypermobility type/Joint Hypermobility Syndrome (EDS-HT/JHS) patients' skin fibroblasts geo:GSE77756
Affymetrix GeneChip miRNA 3.0 profiling of the same JHS/EDS-HT fibroblast cohort as GSE77753. The only public miRNA-level dataset in this disease.
human MICROARRAY n=11 Affymetrix GeneChip miRNA 3.0 Array
dermal fibroblast CL:0002620 Cell Ontology (CL) Relation: this dataset samples this sample type This dataset samples dermal fibroblast, annotated with skin fibroblast (CL:0002620). CL:0002620 is a sample type from the Cell Ontology.
Conditions: Joint hypermobility syndrome / Ehlers-Danlos syndrome hypermobility type Healthy control
PMID:27518164
Show evidence (1 reference)
PMID:27518164 SUPPORT In Vitro
"We compared the DEGs list with the differentially expressed miRNAs to investigate a possible correlation between the expressed miRNA and mRNA in JHS/EDS-HT cells"
The companion miRNA dataset comes from the same study and cohort as the mRNA profiling; this quote is the miRNA-level result specifically, rather than the mRNA transcriptome sentence used for GSE77753.
{ }

Source YAML

click to show 
name: Hypermobile Ehlers-Danlos Syndrome
category: Genetic
creation_date: "2026-06-13T00:00:00Z"
description: >
  Hypermobile Ehlers-Danlos syndrome is a clinically defined Ehlers-Danlos
  subtype characterized by generalized joint hypermobility, joint instability,
  recurrent subluxations or dislocations, chronic pain, soft or
  hyperextensible skin, easy bruising, fatigue, autonomic and gastrointestinal
  symptoms, and other multisystem features. Unlike the monogenic EDS subtypes,
  no validated causal gene or biomarker has been identified, so diagnosis is
  made clinically using the 2017 international criteria.
disease_term:
  preferred_term: Ehlers-Danlos syndrome, hypermobility type
  term:
    id: MONDO:0007523
    label: Ehlers-Danlos syndrome, hypermobility type
synonyms:
- hEDS
- hypermobile EDS
- Ehlers-Danlos syndrome hypermobility type
- Ehlers-Danlos syndrome type III
- EDS type III
parents:
- Ehlers-Danlos Syndrome
- Connective Tissue Disorder
references:
- reference: PMID:20301456
  title: "Hypermobile Ehlers-Danlos Syndrome."
  tags:
  - GeneReviews
  findings:
  - statement: hEDS is diagnosed clinically because no causal etiology has been identified.
  - statement: hEDS management includes exercise, physical therapy, bracing, and symptom-directed care.
- reference: PMID:31409039
  title: "Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers-Danlos Syndromes."
  findings:
  - statement: hEDS/HSD fibroblasts show ECM disorganization and pro-inflammatory myofibroblast-like changes in model studies.
  - statement: hEDS/HSD fibroblast transcriptome shows dysregulated cell-matrix, inflammation, and pain-related genes with candidate aberrant NF-kB and Wnt/beta-catenin signaling.
- reference: PMID:29587413
  title: "Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts."
  findings:
  - statement: hEDS is characterized by generalized joint hypermobility, joint instability complications, minor skin changes, and an unknown molecular basis.
  - statement: In hEDS/HSD fibroblasts the preferentially recruited alpha-v-beta-3 integrin signals through ILK to the transcription factor Snail1, and high MMP9 collagenase degrades the fibronectin ECM, together driving a myofibroblast-like transition.
inheritance:
- name: Autosomal dominant inheritance pattern
  description: >
    Familial hEDS often appears autosomal dominant, but no validated causal gene
    or variant class is available for diagnostic testing.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypermobile EDS is inherited in an autosomal dominant manner with variable expression of signs and variable severity of symptoms among affected family members."
    explanation: GeneReviews describes the observed familial inheritance pattern while separately noting that no causal etiology is known.
progression:
- phase: Lifelong variable multisystem disorder
  age_range: Childhood through adulthood
  notes: >
    hEDS is not modeled as a single fatal degenerative sequence; instead,
    affected individuals have variable lifelong joint instability, pain,
    fatigue, soft-tissue injury, and multisystem manifestations.
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "variable expression of signs and variable severity of symptoms among affected family members."
    explanation: >
      GeneReviews supports variable expression and severity rather than a
      fixed monogenic progression sequence.
- phase: Recurrent instability and chronic symptom burden
  age_range: Any age after onset
  notes: >
    Recurrent subluxations or dislocations and soft-tissue injuries can lead to
    chronic pain, fatigue, functional impairment, and repeated supportive care
    needs.
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
    explanation: >
      This supports recurrent injury/instability as a recurring clinical course
      feature in hEDS.
pathophysiology:
- name: Unresolved ECM remodeling and joint-stability failure
  description: >
    hEDS lacks a validated monogenic cause. Current model evidence points to
    abnormal collagen/fibronectin extracellular-matrix organization,
    excessive matrix remodeling, and pro-inflammatory myofibroblast-like
    fibroblast changes as candidate mechanisms that may contribute to joint
    instability, chronic pain, fatigue, and multisystem symptoms.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: ABNORMAL
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Currently, no underlying genetic, epigenetic, or metabolomic etiology has been identified for hEDS."
    explanation: GeneReviews supports keeping the primary etiology unresolved.
  - reference: PMID:31409039
    reference_title: "Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers-Danlos Syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "skin fibroblasts show a disorganization of the ECM like that observed in cells derived from the other EDS types."
    explanation: This model-based review supports ECM disorganization as a candidate mechanism while not establishing a causal gene.
  - reference: PMID:31409039
    reference_title: "Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers-Danlos Syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hEDS/HSD, cEDS, and vEDS fibroblasts exhibit a marked disorganization of collagen and fibronectin ECM and their specific α2β1 and α5β1 integrin receptors and showed the preferential expression of the αvβ3 integrin"
    explanation: >
      Patient-fibroblast studies point to loss of the canonical collagen and
      fibronectin integrin receptors with preferential αvβ3 integrin
      recruitment as a candidate hEDS matrix-remodeling mechanism.
  downstream:
  - target: Joint instability and chronic pain
    description: >
      Weak or dysregulated connective-tissue support permits recurrent
      subluxations, dislocations, soft-tissue injury, and chronic pain.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301456
      reference_title: "Hypermobile Ehlers-Danlos Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
      explanation: GeneReviews describes the downstream joint-instability phenotype.
  - target: Myofibroblast-like fibroblast transition
    description: >
      In vitro hEDS/HSD fibroblasts show a candidate pro-inflammatory
      myofibroblast-like phenotype mediated through alpha-v-beta-3
      integrin/ILK/Snail1 signaling.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29587413
      reference_title: "Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In hEDS and HSD cells, the αvβ3 integrin was shown to be involved in the fibroblast-to-myofibroblast transition by a transduction pathway involving ILK that signals to the transcription factor Snail1"
      explanation: >
        Patient-cell data support a distinct candidate fibroblast signaling
        branch while hEDS etiology remains unresolved.
- name: Joint instability and chronic pain
  description: >
    Dysregulated connective-tissue support and recurrent soft-tissue injury
    manifest clinically as subluxations, dislocations, acute injury pain, and
    chronic pain.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: ABNORMAL
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
    explanation: >
      GeneReviews supports recurrent instability and soft-tissue injury as the
      clinical downstream consequence.
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic pain, distinct from that associated with acute injury, is common and often neuropathic in nature."
    explanation: >
      GeneReviews supports chronic pain as part of this downstream clinical
      branch.
  downstream:
  - target: Joint hypermobility
    description: >
      Joint-stability failure in hEDS presents clinically as generalized joint
      hypermobility.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301456
      reference_title: "Hypermobile Ehlers-Danlos Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility"
      explanation: GeneReviews identifies generalized joint hypermobility as a core hEDS feature.
  - target: Joint dislocation
    description: >
      Joint instability predisposes to recurrent subluxations and dislocations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301456
      reference_title: "Hypermobile Ehlers-Danlos Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
      explanation: GeneReviews directly links hEDS joint instability to subluxations and dislocations.
  - target: Chronic pain
    description: >
      Repeated joint and soft-tissue injury contributes to chronic pain beyond
      acute injury pain.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - repeated soft-tissue injury
    evidence:
    - reference: PMID:20301456
      reference_title: "Hypermobile Ehlers-Danlos Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Degenerative joint and chronic soft tissue disorders may arise due to repeated injury. Chronic pain, distinct from that associated with acute injury, is common and often neuropathic in nature."
      explanation: GeneReviews links repeated injury with chronic soft-tissue disorders and chronic pain.
  - target: Arthralgia
    description: >
      Joint instability and repeated injury produce joint pain.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - recurrent subluxation or soft-tissue injury
    evidence:
    - reference: ORPHA:285
      reference_title: "Hypermobile Ehlers-Danlos syndrome"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "HP:0002829 | Arthralgia | Very frequent (99-80%)"
      explanation: Orphanet lists arthralgia as a very frequent hEDS feature.
- name: Myofibroblast-like fibroblast transition
  description: >
    hEDS/HSD patient fibroblasts can acquire a migrating myofibroblast-like
    phenotype with alpha-smooth muscle actin stress fibers, cadherin-11, MMP9,
    and inflammatory mediator changes through alpha-v-beta-3
    integrin/ILK/Snail1 signaling. This remains model evidence rather than a
    validated diagnostic biomarker.
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: ABNORMAL
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:31409039
    reference_title: "Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers-Danlos Syndromes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our in vitro studies confirmed the phenotypic conversion of hEDS/HSD fibroblasts into migrating myofibroblast-like cells"
    explanation: >
      This review summarizes patient-cell evidence for a candidate
      myofibroblast-like transition in hEDS/HSD.
  - reference: PMID:29587413
    reference_title: "Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In hEDS and HSD cells, the αvβ3 integrin was shown to be involved in the fibroblast-to-myofibroblast transition by a transduction pathway involving ILK that signals to the transcription factor Snail1"
    explanation: >
      The primary cell-model paper supports the integrin/ILK/Snail1 branch.
  - reference: PMID:29587413
    reference_title: "Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "hEDS and HSD cells exhibit a peculiar in vitro myofibroblast-like phenotype characterized by organization of the α-smooth muscle actin (α-SMA) cytoskeleton, expression of the cadherin-11, and enhanced migratory capability, probably because they synthesize high levels of MMP9, a collagenase also able to digest FN into proteolytic fragments"
    explanation: >
      Patient fibroblasts show the α-SMA/cadherin-11 myofibroblast markers and
      high MMP9 collagenase, providing a candidate ECM-degrading mechanism that
      generates fibronectin fragments driving the transition.
phenotypes:
- name: Joint hypermobility
  description: Generalized joint hypermobility is the central diagnostic musculoskeletal feature of hEDS.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility"
    explanation: GeneReviews identifies generalized joint hypermobility as a core hEDS feature.
- name: Joint dislocation
  description: Joint instability can cause recurrent subluxations or dislocations.
  phenotype_term:
    preferred_term: Joint dislocation
    term:
      id: HP:0001373
      label: Joint dislocation
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subluxations, dislocations, and soft tissue injury are common; they may occur spontaneously or with minimal trauma and can be acutely painful."
    explanation: GeneReviews directly supports recurrent subluxations and dislocations.
- name: Chronic pain
  description: Chronic pain is common and may be distinct from acute injury pain.
  phenotype_term:
    preferred_term: Chronic pain
    term:
      id: HP:0012532
      label: Chronic pain
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic pain, distinct from that associated with acute injury, is common and often neuropathic in nature."
    explanation: GeneReviews directly supports chronic pain in hEDS.
- name: Hyperextensible skin
  description: Soft or mildly hyperextensible skin can occur in hEDS.
  phenotype_term:
    preferred_term: Hyperextensible skin
    term:
      id: HP:0000974
      label: Hyperextensible skin
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pain, soft and hyperextensible skin with atrophic scars and easy bruising"
    explanation: GeneReviews lists soft and hyperextensible skin among hEDS features.
- name: Easy bruising
  description: Easy bruising is a common minor tissue-fragility feature in hEDS.
  phenotype_term:
    preferred_term: Easy bruising
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pain, soft and hyperextensible skin with atrophic scars and easy bruising"
    explanation: GeneReviews lists easy bruising among hEDS clinical features.
- name: Fatigue
  description: Chronic fatigue is a common multisystem manifestation.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
    explanation: GeneReviews lists chronic fatigue among common hEDS manifestations.
- name: Orthostatic tachycardia
  description: Cardiovascular autonomic dysfunction, including POTS-like orthostatic tachycardia, can occur in hEDS.
  phenotype_term:
    preferred_term: Orthostatic tachycardia
    term:
      id: HP:0012173
      label: Orthostatic tachycardia
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
    explanation: >
      GeneReviews lists cardiovascular autonomic dysfunction among common hEDS
      manifestations; orthostatic tachycardia captures the common POTS-like
      autonomic phenotype highlighted by hEDS reviews.
- name: Migraine
  description: Migraine is a reported neurologic manifestation in hEDS.
  phenotype_term:
    preferred_term: Migraine
    term:
      id: HP:0002076
      label: Migraine
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sleep disorders including apnea, migraine"
    explanation: GeneReviews includes migraine among common hEDS manifestations.
- name: Sleep disturbance
  description: Sleep disorders, including apnea, can occur as part of the hEDS multisystem phenotype.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sleep disorders including apnea, migraine"
    explanation: GeneReviews includes sleep disorders among common hEDS manifestations.
- name: Soft skin
  description: Soft skin is a frequent cutaneous feature of hEDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Soft skin
    term:
      id: HP:0000977
      label: Soft skin
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0000977 | Soft skin | Frequent (79-30%)"
    explanation: Orphanet lists soft skin as a frequent hEDS phenotype.
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pain, soft and hyperextensible skin with atrophic scars and easy bruising"
    explanation: GeneReviews lists soft skin among hEDS clinical features.
- name: Arthralgia
  description: Joint pain is a very frequent musculoskeletal manifestation in hEDS.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0002829 | Arthralgia | Very frequent (99-80%)"
    explanation: Orphanet lists arthralgia as very frequent.
- name: Myalgia
  description: Muscle pain is a very frequent pain manifestation in the Orphanet hEDS profile.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0003326 | Myalgia | Very frequent (99-80%)"
    explanation: Orphanet lists myalgia as very frequent.
- name: Dental crowding
  description: Dental crowding is a frequent oral and craniofacial feature of hEDS.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dental crowding
    term:
      id: HP:0000678
      label: Dental crowding
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0000678 | Dental crowding | Frequent (79-30%)"
    explanation: Orphanet lists dental crowding as frequent.
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dental crowding, abdominal hernias, pelvic organ prolapse"
    explanation: GeneReviews lists dental crowding among hEDS clinical characteristics.
- name: Mitral valve prolapse
  description: Mitral valve prolapse is a frequent cardiovascular feature in the Orphanet hEDS profile.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Mitral valve prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0001634 | Mitral valve prolapse | Frequent (79-30%)"
    explanation: Orphanet lists mitral valve prolapse as frequent.
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mitral valve prolapse, and aortic root dilatation."
    explanation: GeneReviews lists mitral valve prolapse among hEDS clinical characteristics.
- name: Gastrointestinal dysmotility
  description: Functional bowel and gastrointestinal motility symptoms are part of the multisystem hEDS phenotype.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Gastrointestinal dysmotility
    term:
      id: HP:0002579
      label: Gastrointestinal dysmotility
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0002579 | Gastrointestinal dysmotility | Occasional (29-5%)"
    explanation: Orphanet lists gastrointestinal dysmotility as occasional.
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic fatigue, functional bowel disorders, cardiovascular autonomic dysfunction"
    explanation: GeneReviews lists functional bowel disorders among common hEDS manifestations.
- name: Acrocyanosis
  description: Acrocyanosis is a very frequent vascular/autonomic feature in the Orphanet hEDS profile.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Acrocyanosis
    term:
      id: HP:0001063
      label: Acrocyanosis
  evidence:
  - reference: ORPHA:285
    reference_title: "Hypermobile Ehlers-Danlos syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0001063 | Acrocyanosis | Very frequent (99-80%)"
    explanation: Orphanet lists acrocyanosis as very frequent.
- name: Atrophic scars
  description: Atrophic scarring accompanies the soft, mildly hyperextensible skin of hEDS.
  phenotype_term:
    preferred_term: Atrophic scars
    term:
      id: HP:0001075
      label: Atrophic scars
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "soft and hyperextensible skin with atrophic scars and easy bruising"
    explanation: GeneReviews lists atrophic scars among the cutaneous features of hEDS.
- name: Aortic root dilatation
  description: >
    Aortic root dilatation can occur in hEDS but, when present, is typically mild
    and not associated with an increased risk of cardiac complications.
  phenotype_term:
    preferred_term: Aortic root dilatation
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mitral valve prolapse and aortic root dilatation, when present, are typically of a mild degree with no increased risk of cardiac complications."
    explanation: >
      GeneReviews lists aortic root dilatation as a hEDS cardiovascular feature
      and notes that it is typically mild.
- name: Peripheral neuropathy
  description: Entrapment and peripheral neuropathies are common neurologic manifestations in hEDS.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "entrapment and peripheral neuropathies"
    explanation: GeneReviews lists entrapment and peripheral neuropathies among common hEDS manifestations.
- name: Anxiety
  description: Anxiety disorders are a common neurobehavioral comorbidity in hEDS.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "anxiety disorders, and urogynecologic disorders are common."
    explanation: GeneReviews lists anxiety disorders among common hEDS manifestations.
- name: Pelvic organ prolapse
  description: Pelvic organ prolapse reflects the connective-tissue laxity of hEDS.
  phenotype_term:
    preferred_term: Pelvic organ prolapse
    term:
      id: HP:0031607
      label: Pelvic organ prolapse
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abdominal hernias, pelvic organ prolapse, marfanoid body habitus"
    explanation: GeneReviews lists pelvic organ prolapse among hEDS clinical characteristics.
treatments:
- name: Exercise-based physical therapy and joint stabilization
  description: >
    hEDS care is symptom-directed and includes progressive strengthening,
    proprioceptive exercise, braces or splints, assistive devices, and avoidance
    of activities that provoke subluxation or pain.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tailored treatment with exercise to increase core and extremity muscle strength and tone, proprioception, and joint stability"
    explanation: GeneReviews supports exercise-based treatment aimed at strength, proprioception, and stability.
- name: Multisystem symptom management
  description: >
    Pain, autonomic, gastrointestinal, oral, neurologic, sleep, psychiatric, and
    urogynecologic manifestations are managed with individualized supportive
    care and surveillance.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surveillance: Assess for joint manifestations, pain, disability, bleeding issues, functional bowel disorders, autonomic dysfunction"
    explanation: GeneReviews supports periodic multisystem assessment and symptom-directed care.
datasets:
- accession: geo:GSE218012
  title: >-
    Whole-transcriptome analysis of dermal fibroblasts from patients with
    hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders
    supports their categorization as a single clinical entity with a
    contribution of inflammatory pathways
  description: >-
    Amplicon-based RNA-seq of cultured dermal fibroblasts from 20 hEDS patients,
    20 HSD patients, and 40 healthy donors. The largest public hEDS omics
    resource, and the only one powered to test whether a transcriptional
    boundary separates hEDS from HSD. Note that sample_count (200) is the GEO
    GSM sample count and is distinct from the 80 donors; the GEO series lists
    biological and technical replicates per donor as separate samples.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 200
  sample_types:
  - preferred_term: dermal fibroblast
    tissue_term:
      preferred_term: dermis
      term:
        id: UBERON:0002067
        label: dermis
    cell_type_term:
      preferred_term: skin fibroblast
      term:
        id: CL:0002620
        label: skin fibroblast
  conditions:
  - Hypermobile Ehlers-Danlos syndrome
  - Hypermobility spectrum disorder
  - Healthy donor control
  platform: GPL23934 Ion Torrent S5 (Homo sapiens)
  publication: PMID:36552803
  evidence:
  - reference: PMID:36552803
    reference_title: >-
      RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos
      Syndrome and Hypermobility Spectrum Disorders Supports Their
      Categorization as a Single Entity with Involvement of Extracellular Matrix
      Degrading and Proinflammatory Pathomechanisms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We demonstrated that both cell types show a common cellular trait, i.e.,
      generalized extracellular matrix (ECM) disarray, myofibroblast
      differentiation, and dysregulated gene expression.
    explanation: >-
      The associated publication reports that hEDS and HSD fibroblasts share the
      ECM-disarray and myofibroblast phenotype, which is the claim this dataset
      is cited to support.
- accession: geo:GSE77753
  title: >-
    Microarray expression data from five Ehlers-Danlos Syndrome Hypermobility
    type/Joint Hypermobility Syndrome (EDS-HT/JHS) patients' skin fibroblasts
  description: >-
    Affymetrix Gene 1.0 ST transcriptome profiling of skin fibroblasts from five
    JHS/EDS-HT (legacy hEDS nomenclature) patients versus six healthy
    individuals. Small but independent of the later RNA-seq cohort, so usable as
    a replication set.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 11
  sample_types:
  - preferred_term: dermal fibroblast
    tissue_term:
      preferred_term: dermis
      term:
        id: UBERON:0002067
        label: dermis
    cell_type_term:
      preferred_term: skin fibroblast
      term:
        id: CL:0002620
        label: skin fibroblast
  conditions:
  - Joint hypermobility syndrome / Ehlers-Danlos syndrome hypermobility type
  - Healthy control
  platform: Affymetrix Human Gene 1.0 ST Array
  publication: PMID:27518164
  evidence:
  - reference: PMID:27518164
    reference_title: >-
      Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients
      with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility
      Type.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Transcriptome analysis indicated perturbation of different signaling
      cascades that are required for homeostatic regulation either during
      development or in adult tissues
    explanation: >-
      The associated publication defines the transcriptomic content of this
      dataset.
- accession: geo:GSE77756
  title: >-
    microRNA expression profile from five Ehlers-Danlos Syndrome Hypermobility
    type/Joint Hypermobility Syndrome (EDS-HT/JHS) patients' skin fibroblasts
  description: >-
    Affymetrix GeneChip miRNA 3.0 profiling of the same JHS/EDS-HT fibroblast
    cohort as GSE77753. The only public miRNA-level dataset in this disease.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 11
  sample_types:
  - preferred_term: dermal fibroblast
    tissue_term:
      preferred_term: dermis
      term:
        id: UBERON:0002067
        label: dermis
    cell_type_term:
      preferred_term: skin fibroblast
      term:
        id: CL:0002620
        label: skin fibroblast
  conditions:
  - Joint hypermobility syndrome / Ehlers-Danlos syndrome hypermobility type
  - Healthy control
  platform: Affymetrix GeneChip miRNA 3.0 Array
  publication: PMID:27518164
  evidence:
  - reference: PMID:27518164
    reference_title: >-
      Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients
      with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility
      Type.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We compared the DEGs list with the differentially expressed miRNAs to
      investigate a possible correlation between the expressed miRNA and mRNA in
      JHS/EDS-HT cells
    explanation: >-
      The companion miRNA dataset comes from the same study and cohort as the
      mRNA profiling; this quote is the miRNA-level result specifically, rather
      than the mRNA transcriptome sentence used for GSE77753.
discussions:
- discussion_id: gap_heds_causal_architecture
  prompt: >-
    Is hEDS a locus-heterogeneous Mendelian disorder, a common-variant complex
    trait, or a composite of both?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  - inheritance#Autosomal dominant inheritance pattern
  rationale: >-
    The entry records autosomal dominant transmission, but no causal gene has
    been validated. Exome sequencing of diagnostically unresolved EDS found
    candidate loci without genome-wide significance, a GWAS meta-analysis found
    common-variant contributions, and a KLK15 missense variant segregated in two
    families with a supporting knock-in mouse. These three results are
    compatible with very different disease architectures, and the choice between
    them determines whether diagnostic sequencing is even the right instrument.
  proposed_experiments:
  - experiment_id: exp_heds_joint_architecture_partition
    name: Joint rare-variant and common-variant architecture partition
    description: >-
      Partition hEDS liability across rare and common variation in a single
      analysis rather than in separate studies. Combine the HEDGE whole-genome
      cohort with published GWAS summary statistics to estimate SNP-based
      heritability, gene-level rare-variant burden, and the fraction of familial
      recurrence each explains. Include an explicit replication arm for KLK15
      and the wider kallikrein family in unrelated probands.
    experiment_type:
      preferred_term: statistical genetics architecture partition
    decision_criterion: >-
      Whether rare-variant burden or common-variant polygenic score explains the
      larger share of liability, and whether kallikrein-family burden replicates
      outside the discovery cohort. A monogenic or oligogenic architecture is
      indicated if replicated rare-variant burden dominates and segregates in
      families; a complex-trait architecture if SNP-based heritability dominates
      and no gene reaches exome-wide significance, which would also remove the
      expectation that a single validated causal gene is the endpoint of hEDS
      genetics.
    would_support:
    - inheritance#Autosomal dominant inheritance pattern
    would_refute:
    - inheritance#Autosomal dominant inheritance pattern
  evidence:
  - reference: PMID:37813462
    reference_title: Genetic complexity of diagnostically unresolved Ehlers-Danlos syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic burden analysis revealed a number of novel loci, although none
      reached the threshold for genome-wide significance.
    explanation: >-
      Exome sequencing of unresolved EDS patients failed to identify a
      significant locus, which is the primary evidence that hEDS is not a
      simple monogenic disorder.
  - reference: PMID:41001447
    reference_title: >-
      Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos
      Syndrome: Insights from Genome-Wide Association Study Meta-analysis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast to other EDS subtypes with defined genetic causes, the
      molecular basis of hEDS has remained elusive.
    explanation: >-
      The GWAS meta-analysis states the unresolved molecular basis that motivates
      this gap, and supplies the common-variant arm of the competing hypotheses.
  - reference: PMID:38947032
    reference_title: Variants in the Kallikrein Gene Family and Hypermobile Ehlers-Danlos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A missense variant in Kallikrein-15 (KLK15 p. Gly226Asp), segregated with
      disease in two families
    explanation: >-
      The human-genetic arm of the monogenic hypothesis: KLK15 segregates with
      disease in two families. Partial rather than full support because the
      finding is unreplicated outside the discovery cohort.
  - reference: PMID:38947032
    reference_title: Variants in the Kallikrein Gene Family and Hypermobile Ehlers-Danlos Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      genetic burden analyses of 197 sporadic hEDS patients revealed enrichment
      of variants within the Kallikrein gene family
    explanation: >-
      Extends the single-family signal to a sporadic cohort, which is the
      observation the proposed replication arm of the architecture-partition
      experiment would test.
  - reference: PMID:38947032
    reference_title: Variants in the Kallikrein Gene Family and Hypermobile Ehlers-Danlos Syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Consistent with our clinical cohort, Klk15G224D/+ mice displayed
      structural and functional connective tissue defects within multiple organ
      systems.
    explanation: >-
      Knock-in mouse recapitulates multisystem connective tissue defects. Kept
      as a separate MODEL_ORGANISM item so the animal evidence is not scored as
      human genetic support for the monogenic arm.
- discussion_id: gap_heds_hsd_boundary
  prompt: >-
    Is the 2017 criteria-based split between hEDS and hypermobility spectrum
    disorder biologically real, or an artifact of a threshold-based checklist?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  - pathophysiology#Myofibroblast-like fibroblast transition
  rationale: >-
    Two independent molecular datasets from the same group point the same way:
    dermal fibroblast RNA-seq across 20 hEDS and 20 HSD patients found a shared
    cellular phenotype, and plasma ECM-fragmentation profiling found a shared
    fibronectin and collagen-I signature. If no molecular boundary exists, the
    dismech decision to keep separate hEDS and HSD framing needs an explicit
    justification, and cohort assembly for every other hEDS question is affected.
  proposed_experiments:
  - experiment_id: exp_heds_hsd_blinded_molecular_classifier
    name: Blinded molecular classifier for the hEDS/HSD boundary
    description: >-
      Train a classifier on GSE218012 dermal fibroblast RNA-seq to separate hEDS
      from HSD, with healthy donors as a positive-control contrast, using nested
      cross-validation and label permutation to establish the null. Repeat on
      plasma ECM-fragment profiles from an independent cohort.
    experiment_type:
      preferred_term: supervised classification of transcriptomic profiles
    decision_criterion: >-
      Whether hEDS-versus-HSD classification accuracy exceeds the permuted null,
      given that the same pipeline separates patients from healthy donors. A
      real biological boundary is indicated if hEDS and HSD separate above the
      null; a single-entity model if the two are inseparable while both separate
      from controls, which would mean the 2017 criteria threshold does not track
      a molecular distinction and that these nodes describe one shared substrate
      rather than an hEDS-specific one.
    would_support:
    - pathophysiology#Unresolved ECM remodeling and joint-stability failure
    - pathophysiology#Myofibroblast-like fibroblast transition
    would_refute:
    - pathophysiology#Unresolved ECM remodeling and joint-stability failure
    - pathophysiology#Myofibroblast-like fibroblast transition
  evidence:
  - reference: PMID:39225014
    reference_title: >-
      Bridging the Diagnostic Gap for Hypermobile Ehlers-Danlos Syndrome and
      Hypermobility Spectrum Disorders: Evidence of a Common Extracellular
      Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      supporting their classification as a single disorder and prompting
      reconsideration of the hEDS criteria
    explanation: >-
      The plasma biomarker study explicitly argues that hEDS and HSD should be
      treated as one entity, which is the controversy recorded here.
  - reference: PMID:36552803
    reference_title: >-
      RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos
      Syndrome and Hypermobility Spectrum Disorders Supports Their
      Categorization as a Single Entity with Involvement of Extracellular Matrix
      Degrading and Proinflammatory Pathomechanisms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We demonstrated that both cell types show a common cellular trait, i.e.,
      generalized extracellular matrix (ECM) disarray, myofibroblast
      differentiation, and dysregulated gene expression.
    explanation: >-
      Independent transcriptomic evidence that hEDS and HSD fibroblasts share
      the same cellular phenotype.
- discussion_id: gap_heds_criterion3_exclusion_boundary
  prompt: >-
    What is the minimum sufficient genetic workup before criterion 3 of the 2017
    criteria (exclusion of alternative diagnoses) can be considered satisfied?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  rationale: >-
    hEDS is a diagnosis of exclusion, but the exclusion set is undefined. In a
    single-center series, a quarter of patients who already met all three 2017
    criteria were found on genetic testing to have an alternative or additional
    diagnosis with different management. Without a specified panel, criterion 3
    is unfalsifiable and cohort purity varies by center, which contaminates every
    downstream hEDS study including the genetic ones.
  proposed_experiments:
  - experiment_id: exp_heds_exclusion_panel_yield_curve
    name: Diagnostic-yield curve for a defined hEDS exclusion panel
    description: >-
      Assemble a candidate exclusion gene set from the EDS, Loeys-Dietz,
      heritable thoracic aortic disease, and EDS-mimicking Mendelian disorder
      panels, annotated with ClinGen gene-disease validity and dosage
      sensitivity. Apply it retrospectively to consecutive criteria-positive
      hEDS cohorts and plot reclassification yield against panel size to find
      where the curve flattens.
    experiment_type:
      preferred_term: retrospective diagnostic yield analysis
    decision_criterion: >-
      The panel size at which incremental reclassification yield falls below a
      pre-specified threshold. A bounded minimum panel that makes criterion 3
      operational is indicated if the curve flattens; a high sustained
      reclassification yield would instead mean criteria-positive cohorts are
      substantially contaminated by alternative diagnoses, undermining the
      cohort basis on which this node's mechanism evidence rests.
    would_support:
    - pathophysiology#Unresolved ECM remodeling and joint-stability failure
    would_refute:
    - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  evidence:
  - reference: PMID:40428350
    reference_title: >-
      Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of
      Genetic Testing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic testing identified an alternative or additional diagnosis in 47 of
      these individuals (26.4%), with clinical implications requiring distinct
      management strategies.
    explanation: >-
      Quantifies how often criteria-positive hEDS patients carry an alternative
      diagnosis, establishing that criterion 3 is currently under-enforced.
- discussion_id: gap_heds_dysautonomia_mechanism
  prompt: >-
    What mechanistic chain connects a connective-tissue defect to the small-fiber
    neuropathy, orthostatic cerebral hypoperfusion, and POTS seen in most hEDS
    patients?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  - phenotypes#Orthostatic tachycardia
  - phenotypes#Peripheral neuropathy
  - phenotypes#Gastrointestinal dysmotility
  rationale: >-
    Deep phenotyping shows the neurologic and autonomic burden is near-universal
    rather than incidental, yet gastroenterology guidance states plainly that the
    biological mechanisms behind these associations are not established. The
    dismech entry currently carries orthostatic tachycardia, peripheral
    neuropathy, and GI dysmotility as phenotypes with no causal edge from any
    pathophysiology node, which faithfully reflects the state of knowledge and
    marks exactly where the model is incomplete.
  proposed_experiments:
  - experiment_id: exp_heds_neuroimmune_locus_to_nerve_bridge
    name: Genotype-anchored small-fiber neuropathy stratification
    description: >-
      Stratify a deeply phenotyped hEDS cohort with skin biopsy intraepidermal
      nerve fiber density, autonomic function testing, and transcranial Doppler
      cerebral blood flow by genotype at the GWAS-implicated regulatory locus,
      using GTEx tibial nerve as the eQTL reference tissue. Test whether risk
      allele carriers show greater fiber loss or cerebral hypoperfusion than
      non-carriers with equivalent joint phenotypes.
    experiment_type:
      preferred_term: genotype-stratified deep phenotyping study
    decision_criterion: >-
      Whether neuropathic and cerebrovascular measures differ by genotype at the
      candidate locus after adjustment for joint-phenotype severity. A genotype
      effect surviving that adjustment indicates a neuroimmune arm partly
      independent of the ECM arm, and would require a pathophysiology node this
      entry does not yet have; no genotype effect is consistent with a purely
      mechanical model in which the autonomic and neuropathic phenotypes are
      secondary to connective-tissue laxity alone.
    would_support:
    - phenotypes#Orthostatic tachycardia
    - phenotypes#Peripheral neuropathy
    would_refute:
    - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  evidence:
  - reference: PMID:40387691
    reference_title: >-
      AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune
      Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      while theoretical explanations exist, experimental evidence of the
      biological mechanisms that explain relationships is limited and evolving
    explanation: >-
      A society expert review stating directly that the mechanism behind the
      hEDS/POTS/MCAS association is unestablished.
  - reference: PMID:40843452
    reference_title: >-
      Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and
      Neuropathic Features.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small fiber neuropathy using structural criteria was detected in 64%, and
      using combined structural and functional criteria in 82%.
    explanation: >-
      Establishes that small-fiber neuropathy is a majority finding in hEDS,
      making its absent mechanistic explanation a first-order gap.
  - reference: PMID:40843452
    reference_title: >-
      Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and
      Neuropathic Features.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Orthostatic cerebral blood flow velocity was reduced in 79% of hEDS and
      correlated with orthostatic dizziness.
    explanation: >-
      Provides the cerebrovascular readout that a mechanistic model would need
      to explain.
- discussion_id: gap_heds_fascia_versus_dermis_substrate
  prompt: >-
    Is fascia, rather than dermis, the primary affected tissue in hEDS, and is
    the dermal fibroblast phenotype a proxy for it?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Myofibroblast-like fibroblast transition
  - pathophysiology#Joint instability and chronic pain
  rationale: >-
    Every molecular dataset in this entry is derived from dermal fibroblasts,
    because skin is what is easy to biopsy. A fascia-centered model proposes that
    the clinically relevant substrate is deep fascia, where thickness,
    interfascial gliding, and stiffness abnormalities have been reported. If
    correct, the dermal fibroblast phenotype the pathophysiology nodes rest on is
    an accessible surrogate rather than the affected tissue, and no public
    fascia-specific omics dataset exists to test this.
  proposed_experiments:
  - experiment_id: exp_heds_paired_fascia_dermis_transcriptome
    name: Paired fascia and dermis transcriptomic comparison
    description: >-
      Collect paired deep fascia and dermis biopsies from the same hEDS patients
      and matched controls, with ultrasound measurement of fascial thickness and
      interfascial gliding at the biopsy site. Compare the ECM-remodeling and
      myofibroblast signatures between tissues within each patient, so that
      tissue effect is estimated independently of between-patient variation.
    experiment_type:
      preferred_term: paired-tissue transcriptomic comparison
    decision_criterion: >-
      Whether the disease signature is stronger in fascia than in paired dermis
      from the same individual, and whether it tracks the imaging measures.
      Concordance between the two tissues validates dermal fibroblasts as a
      surrogate and leaves these nodes standing; a signature confined to or
      much stronger in fascia indicates a fascia-primary model, and would mean
      the dermal fibroblast findings cannot be read directly as the
      tissue-level mechanism of joint instability.
    would_support:
    - pathophysiology#Myofibroblast-like fibroblast transition
    - pathophysiology#Joint instability and chronic pain
    would_refute:
    - pathophysiology#Myofibroblast-like fibroblast transition
  evidence:
  - reference: PMID:40565051
    reference_title: >-
      Fascial Pathophysiology in Hypermobility Spectrum Disorders and Hypermobile
      Ehlers-Danlos Syndrome: A Review of Emerging Evidence.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      By reframing hEDS and HSD as disorders of pathological fascial remodeling,
      this review offers an integrated model that connects molecular mechanisms
      with clinical expression.
    explanation: >-
      States the competing tissue-level model that this open question is about.
  - reference: PMID:40565051
    reference_title: >-
      Fascial Pathophysiology in Hypermobility Spectrum Disorders and Hypermobile
      Ehlers-Danlos Syndrome: A Review of Emerging Evidence.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      It underscores the urgent need for multidisciplinary research to define
      diagnostic biomarkers, clarify therapeutic targets
    explanation: >-
      The review itself frames these as unresolved research needs rather than
      established findings.
- discussion_id: gap_heds_sex_ratio
  prompt: >-
    Why is hEDS diagnosed in women several times more often than in men despite
    apparently autosomal dominant transmission?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - inheritance#Autosomal dominant inheritance pattern
  rationale: >-
    Clinic series report female-to-male ratios of roughly 7:1 for hEDS and higher
    still for HSD, which is irreconcilable with autosomal dominant inheritance
    unless sex modifies penetrance, expressivity, or ascertainment. The competing
    explanations (hormonal modulation of connective tissue, sex differences in
    pain reporting, referral and diagnostic bias) have different consequences:
    one is disease biology that belongs in the pathograph, the others are study
    design artifacts that would bias every hEDS cohort assembled to date.
  proposed_experiments:
  - experiment_id: exp_heds_sex_ratio_ascertainment_decomposition
    name: Ascertainment-controlled sex ratio decomposition
    description: >-
      Compare the hEDS sex ratio between referral-based clinic cohorts and
      population-based sampling frames such as biobank or national registry
      cohorts ascertained on diagnosis codes rather than specialist referral.
      Within families, compare penetrance in male versus female first-degree
      relatives of affected probands, which holds genotype risk approximately
      constant across sexes.
    experiment_type:
      preferred_term: ascertainment bias decomposition
    decision_criterion: >-
      Whether the sex ratio persists in population-based and within-family
      sampling after removing referral-based ascertainment. Persistence within
      families indicates sex-modified penetrance as real disease biology, which
      would qualify the plain autosomal dominant model recorded here; a ratio
      collapsing toward 1:1 under population sampling indicates a purely
      ascertainment-driven explanation and leaves the inheritance model intact.
    would_support:
    - inheritance#Autosomal dominant inheritance pattern
    would_refute:
    - inheritance#Autosomal dominant inheritance pattern
  evidence:
  - reference: PMID:41993759
    reference_title: >-
      Females with hypermobile Ehlers-Danlos syndrome self-report more sexual
      problems than chronic pain controls without hypermobility, males, or
      patients with hypermobile spectrum disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although hEDS and HSD are autosomal-dominant conditions and would be
      expected to display a 1:1 sex ratio, studies report higher prevalence in
      women.
    explanation: >-
      States the inheritance-versus-observation contradiction that defines this
      gap.
- discussion_id: gap_heds_myofibroblast_causal_dependency
  prompt: >-
    Is the alpha-v-beta-3/ILK/Snail1 myofibroblast transition a causal driver of
    extracellular matrix failure in hEDS, a passenger of the disease state, or a
    mechanotransduction artifact of culture on rigid plastic?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Myofibroblast-like fibroblast transition
  - pathophysiology#Unresolved ECM remodeling and joint-stability failure
  rationale: >-
    The myofibroblast-like transition is the most mechanistically detailed node
    in this entry, but every observation supporting it comes from patient
    fibroblasts grown on tissue-culture plastic, and the node's own description
    already concedes it is model evidence rather than a validated biomarker.
    Substrate rigidity is an independent and sufficient inducer of myofibroblast
    differentiation in disease fibroblasts, so the reported hEDS phenotype is
    confounded by the culture format at the point of measurement. Three outcomes
    are live: the transition is a causal dependency of ECM failure, a passenger
    that tracks disease without driving it, or a stiffness artifact that a soft
    substrate abolishes in patient and control cells alike. The node currently
    carries no downstream causal edges, which is the honest reflection of that
    uncertainty; only the first outcome would justify drawing one, and only the
    first makes the axis a therapeutic target.
  proposed_experiments:
  - experiment_id: exp_heds_myofibroblast_stiffness_controlled_perturbation
    name: Stiffness-controlled perturbation screen of the myofibroblast transition
    description: >-
      Culture a panel of hEDS, HSD, and control dermal fibroblasts across a
      substrate-stiffness series spanning soft matrix and rigid tissue-culture
      plastic, crossed with a bounded perturbation set targeting the proposed
      axis (alpha-v-beta-3 integrin blockade, ILK inhibition, SNAI1 knockdown,
      TGF-beta pathway modulation, MMP9 inhibition). Score alpha-smooth muscle
      actin stress-fiber organization, fibronectin matrix assembly, MMP9
      secretion, and migration by high-content imaging, with the perturbation
      set chosen from the differentially expressed genes in GSE218012. The
      stiffness arm is the control the existing literature lacks, and the
      plate-based readouts make this the one gap in this entry with a protocol
      an autonomous laboratory could compile and run.
    experiment_type:
      preferred_term: high-content perturbation screen
    model_systems:
    - name: Patient-derived dermal fibroblast panel on defined-stiffness substrates
      description: >-
        Primary hEDS, HSD, and control dermal fibroblasts cultured on hydrogels
        of controlled elastic modulus alongside conventional rigid plastic.
      experimental_model_type: PRIMARY_CELL_CULTURE
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
    decision_criterion: >-
      Whether the hEDS-versus-control difference in myofibroblast conversion and
      matrix assembly survives on soft substrate, and whether perturbing the
      alpha-v-beta-3/ILK/Snail1 axis rescues matrix assembly rather than only
      reducing the alpha-smooth muscle actin marker. A causal dependency is
      indicated if axis perturbation restores matrix assembly and the
      patient-control difference persists on soft substrate; a passenger role if
      perturbation removes the marker without restoring matrix assembly; and a
      rigid-culture mechanotransduction artifact rather than hEDS biology if the
      patient-control difference disappears on soft substrate.
    would_support:
    - pathophysiology#Myofibroblast-like fibroblast transition
    would_refute:
    - pathophysiology#Myofibroblast-like fibroblast transition
  evidence:
  - reference: PMID:29587413
    reference_title: >-
      Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial
      Tortuosity Syndromes' Dermal Fibroblasts.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In hEDS and HSD cells, the αvβ3 integrin was shown to be involved in the
      fibroblast-to-myofibroblast transition
    explanation: >-
      Establishes the specific signaling axis this gap proposes to test as a
      causal dependency.
  - reference: PMID:31409039
    reference_title: >-
      Cellular and Molecular Mechanisms in the Pathogenesis of Classical,
      Vascular, and Hypermobile Ehlers-Danlos Syndromes.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our in vitro studies confirmed the phenotypic conversion of hEDS/HSD
      fibroblasts into migrating myofibroblast-like cells
    explanation: >-
      Confirms the observation is reproducible in vitro, which is what makes the
      culture-format confound worth resolving rather than dismissing.
  - reference: PMID:40343813
    reference_title: >-
      Matrix Softness Induces an Afibrogenic Lipofibroblast Phenotype in
      Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      culture in soft microenvironments (as spheroids or on soft
      collagen-coated substrate) redirects myofibroblasts to a
      lipofibroblast-like phenotype
    explanation: >-
      Demonstrates in disease-derived fibroblasts that substrate stiffness alone
      controls myofibroblast identity, establishing the confound that motivates
      the stiffness-controlled arm of the proposed experiment.
  - reference: PMID:40343813
    reference_title: >-
      Matrix Softness Induces an Afibrogenic Lipofibroblast Phenotype in
      Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The fibrogenic effects of TGF-β1 are prevented in fibroblasts cultured in
      soft settings.
    explanation: >-
      Shows that a canonical pro-fibrotic stimulus loses its effect on soft
      substrate, so a stiffness arm is required before any hEDS fibroblast
      phenotype can be called disease biology.
📚

References & Deep Research

References

3
PMID:20301456
Hypermobile Ehlers-Danlos Syndrome.
2 findings
hEDS is diagnosed clinically because no causal etiology has been identified.
hEDS management includes exercise, physical therapy, bracing, and symptom-directed care.
PMID:31409039
Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers-Danlos Syndromes.
2 findings
hEDS/HSD fibroblasts show ECM disorganization and pro-inflammatory myofibroblast-like changes in model studies.
hEDS/HSD fibroblast transcriptome shows dysregulated cell-matrix, inflammation, and pain-related genes with candidate aberrant NF-kB and Wnt/beta-catenin signaling.
PMID:29587413
Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.
2 findings
hEDS is characterized by generalized joint hypermobility, joint instability complications, minor skin changes, and an unknown molecular basis.
In hEDS/HSD fibroblasts the preferentially recruited alpha-v-beta-3 integrin signals through ILK to the transcription factor Snail1, and high MMP9 collagenase degrades the fibronectin ECM, together driving a myofibroblast-like transition.

Deep Research

2
Falcon ▸
Question: You are an expert researcher providing comprehensive, well-cited information.
Edison Scientific Literature 39 citations 2026-06-13T17:24:13.799405

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Prepare a focused, citation-rich deep research report for a dismech Disease entry called 'Hypermobile Ehlers-Danlos Syndrome'. Research objectives: define disease boundary and synonyms including hEDS and EDS hypermobility type; clarify that the molecular basis remains unresolved and diagnosis is clinical; distinguish hEDS from hypermobility spectrum disorders and nonsyndromic generalized joint hypermobility; summarize shared connective-tissue/ECM, pain, proprioceptive, autonomic, gastrointestinal, mast-cell/inflammatory, and psychosocial comorbidity evidence without overstating causality; identify core phenotypes including generalized joint hypermobility, joint instability/subluxation/dislocation, chronic pain, soft or hyperextensible skin, easy bruising, fatigue, dysautonomia/POTS, GI symptoms, and mitral valve/aortic root findings where supported; summarize treatment evidence including physical therapy, exercise/strengthening, pain management, and multidisciplinary care; identify MONDO, HPO, GO, and MAXO terms suitable for dismech YAML; include GeneReviews, 2017 classification/nosology, recent 2023-2024 reviews, and primary studies with PMID identifiers; flag evidence limitations, diagnostic circularity, and lack of validated genetic biomarkers. Do not invent citations; provide exact PMID identifiers for key claims and prefer PubMed-indexed sources.

Hypermobile Ehlers–Danlos Syndrome (hEDS): focused deep research report (for dismech Disease entry)

0) Executive summary

Hypermobile Ehlers–Danlos syndrome (hEDS) is the most common EDS subtype and is defined by a clinical diagnostic framework emphasizing generalized joint hypermobility plus systemic/musculoskeletal features and explicit exclusion of alternative diagnoses; no validated genetic or molecular biomarker is currently available for routine diagnosis, and the molecular basis remains unresolved. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)

A key boundary in contemporary practice is the 2017-era separation of hEDS from hypermobility spectrum disorders (HSD)—the latter covering symptomatic hypermobility presentations that do not meet full hEDS criteria—while nonsyndromic generalized joint hypermobility (GJH) denotes joint laxity without the systemic/persistent symptomatic pattern expected in hEDS/HSD. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 27-30)

Across recent cohorts and reviews, core phenotypes include generalized joint hypermobility with instability/subluxations/dislocations, chronic pain, fatigue, common gastrointestinal symptoms (often functional gut–brain disorders), autonomic complaints including orthostatic intolerance/POTS, and frequent psychosocial comorbidity (anxiety/depression). Associations with mast-cell activation and inflammatory mechanisms are widely discussed but remain unproven as causal; recent GI-focused guidance explicitly states mechanistic links to autonomic dysfunction or mast-cell activation are unclear despite clinical co-occurrence. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2, song2023psychologicalinterventionsfor pages 1-2)

Management is symptom-focused and typically multidisciplinary, centered on patient education, physical therapy/exercise/proprioception and joint stabilization strategies, and multimodal pain care; evidence quality is limited, with persistent gaps in high-quality clinical practice guidelines and randomized trials in several domains (including surgery). (peterson2018physicalandmechanical pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

1) Key concepts, definitions, synonyms, and disease boundary

1.1 Preferred term and synonyms

Recent genetics and clinical reviews describe hypermobile Ehlers–Danlos syndrome as the entity historically referred to as EDS hypermobility type or type III EDS, and overlapping older terminology includes joint hypermobility syndrome (JHS) in some literature. Because outdated nosology contributes to cohort misclassification and irreproducible genetic findings, current work emphasizes contemporary terminology and criteria for research and clinical clarity. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)

1.2 Clinical diagnosis and unresolved molecular basis

Multiple sources emphasize that hEDS is unusual among EDS subtypes in lacking a confirmed monogenic cause and therefore remains a clinical diagnosis. A 2022 critical appraisal of genetic studies states that diagnosis of hEDS “relies solely on a clinical diagnosis since its molecular aetiology remains unknown,” and highlights that the genetics literature is “scant, dispersed and conflicting” partly due to historical terminology and cohort heterogeneity. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

A 2024 clinic cohort likewise states that gene variants unique to hEDS/HSD are unknown (while noting emerging, not-yet-established candidates), reinforcing that the clinical framework remains central. (darakjian2024similaritiesanddifferences pages 1-3)

1.3 2017-era adult diagnostic framework (summary)

Later summaries of the 2017 adult hEDS framework describe three concurrent criteria: - Criterion 1: generalized joint hypermobility (often operationalized by Beighton thresholds that vary by age). (ganesh2024longcovidand pages 2-3) - Criterion 2: additional systemic and/or musculoskeletal features (often structured as “Feature A/B/C” sets, including systemic connective tissue manifestations, family history, and musculoskeletal complications such as chronic pain and recurrent atraumatic dislocations/instability). (forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3) - Criterion 3: exclusion of alternative diagnoses and attention to findings inconsistent with hEDS (e.g., “unusual skin fragility” and exclusion of other heritable/acquired connective-tissue disorders, including autoimmune rheumatologic conditions when relevant). (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8)

An important implementation point is that genetic testing is not confirmatory for hEDS, but can be valuable in Criterion 3 (excluding other syndromic/monogenic disorders). (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

1.4 Boundary distinctions: hEDS vs HSD vs nonsyndromic GJH

  • hEDS vs HSD: The 2017 diagnostic framework separated hEDS from hypermobility spectrum disorders (HSD). In a Mayo Clinic intake cohort (2019–2024) applying 2017 criteria, 66.5% were diagnosed with HSD (n=1389) and 20.3% with hEDS (n=423), illustrating that many symptomatic hypermobility presentations fall outside the more specific hEDS criteria. (darakjian2024similaritiesanddifferences pages 1-3)
  • hEDS/HSD vs nonsyndromic GJH: Reviews of the hypermobility spectrum emphasize that generalized joint hypermobility can occur without the systemic/persistent symptomatic features expected in hEDS/HSD, supporting a conceptual continuum from asymptomatic/nonsyndromic hypermobility to symptomatic HSD to hEDS when full criteria are met. (scicluna2023thegeneticsof pages 27-30)

1.5 Diagnostic circularity and limitations

Because hEDS is defined by a symptom-based framework with nonspecific features, studies of “comorbidities” can become circular if they examine outcomes that overlap with diagnostic criteria (e.g., pain, instability, some systemic features). Large clinic datasets show extensive symptom overlap between hEDS and HSD, underscoring the imperfect boundary and the importance of careful phenotyping and exclusionary evaluation. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

Supporting the importance of exclusionary workups, a 2025 clinical cohort study reported that among 178 patients meeting 2017 hEDS criteria, genetic testing identified an alternative or additional diagnosis in 26.4%, emphasizing that “hypermobility” is a shared phenotype across multiple disorders and that Criterion 3 is clinically consequential. (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2) Current understanding of pathophysiology and mechanistic hypotheses (cautious synthesis)

2.1 Connective tissue/ECM framing

hEDS is classically framed as a heritable connective tissue disorder, with the broader EDS concept centered on joint hypermobility, skin hyperextensibility, and tissue fragility. However, unlike other EDS types, the molecular basis of hEDS remains unknown, and mechanistic accounts (e.g., ECM remodeling, cell–matrix interactions, inflammatory/pain signaling) remain hypotheses requiring further validation. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2.2 Pain and proprioception

Recent clinical summaries emphasize chronic pain and proprioceptive impairment as common and disabling. Pediatric/rehabilitation-oriented evidence describes decreased joint position sense and motion incoordination in hypermobility disorders; however, controlled trial evidence for specific therapies remains limited. (ganesh2024longcovidand pages 3-4, peterson2018physicalandmechanical pages 1-2)

2.3 Autonomic dysfunction / POTS

Autonomic symptoms and POTS are commonly reported alongside hEDS/HSD. A GI-focused clinical review states that autonomic dysfunction (including POTS) has been documented in around 30% of hypermobility-disorder patients and may exacerbate GI symptoms, but mechanistic links remain unclear. (lam2023gastrointestinalsymptomsand pages 1-2)

The same review describes bidirectional clinical co-occurrence estimates: POTS in up to 40% of hypermobility disorders and hypermobility disorders in ~25% of POTS cohorts. (lam2023gastrointestinalsymptomsand pages 3-4)

2.4 Gastrointestinal symptoms

A 2023 Frontline Gastroenterology review describes a high GI symptom burden in hypermobility disorders (hEDS/HSD), with prevalence reported between 30% and 96%, and emphasizes that symptoms are often attributable to disorders of gut–brain interaction rather than proven structural dysmotility; the true prevalence of dysmotility remains unknown due to referral bias, retrospective designs, and confounding medications (notably opioids). (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

Specific estimates in that review include functional dyspepsia “up to 50%” in secondary-care hypermobility-disorder patients and slow colonic transit in 10–20% (with caveats about heterogeneous testing and populations). (lam2023gastrointestinalsymptomsand pages 3-4)

2.5 Mast-cell/inflammatory associations (avoid overstatement)

Mast cell activation syndrome (MCAS) is frequently discussed in hypermobility communities and appears in multidisciplinary clinical conversations. However, the 2023 GI review explicitly states that the role of mast cell activation in GI symptoms is not known despite associations with POTS and suggested links to MCAS; it also warns that some proposed biomarkers (e.g., diamine oxidase) are not reliable and that diagnostic guidelines are often not followed. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)

A genetics/diagnosis-focused review also notes that conditions such as hereditary alpha-tryptasemia can produce symptoms resembling hEDS and recommends baseline tryptase assessment as part of differential diagnosis in appropriate cases, illustrating again that “mast-cell/inflammatory” signals can reflect overlapping diagnoses rather than a proven hEDS mechanism. (forghani2025hypermobileehlers–danlossyndrome pages 6-8)

2.6 Psychosocial comorbidity and illness uncertainty

Psychiatric comorbidity is common in hEDS/HSD and should be interpreted as co-occurring morbidity rather than an explanatory replacement for somatic disease. A 2023 scoping review reports that in one cohort of 106 hypermobile EDS patients, 42.5% had a psychiatric disorder; anxiety and depression were 23.6% and 25.5%, and pain symptoms were associated with nearly 10× increased odds of psychiatric disorder. (song2023psychologicalinterventionsfor pages 1-2)

A 2023 narrative review highlights illness uncertainty in hEDS, attributing it to multisystem complexity, unclear etiology, prolonged diagnostic trajectories, misdiagnosis, and perceived dismissal; it argues for clearer explanations and multidisciplinary best-practice care. (bulbenacabre2017anxiety&joint pages 102-108)

3) Core phenotypes and comorbidities (with recent statistics)

The following phenotype clusters are repeatedly supported across recent cohorts and reviews, with variable evidence strength and likely selection bias toward specialty clinics:

  • Generalized joint hypermobility and instability: In a systematic review of EDS extracutaneous features, joint hypermobility was reported in 153/160 (95.6%) hypermobile EDS cases; a 2024 Mayo clinic cohort reported subluxations in 71.2% of hEDS and 72.6% of HSD patients. (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 1-2)
  • Pain: The systematic review reported chronic pain in hypermobile EDS 139/157 (88.5%); the 2024 Mayo cohort reported joint pain in 82.0% of hEDS vs 88.9% of HSD. (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 1-2)
  • Fatigue: The systematic review found chronic fatigue in hypermobile EDS 61/63 (96.8%), and comparative clinic studies summarized in 2024 work report >40% fatigue in tertiary-care settings. (darakjian2024similaritiesanddifferences pages 8-9, lam2023gastrointestinalsymptomsand pages 1-2)
  • GI symptoms: Mayo cohort prevalences included nausea 54.6% (hEDS) vs 59.5% (HSD) and constipation 53.0% vs 57.2%; broader reviews report GI symptom prevalence 30–96%. (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 2-3)
  • Headache/migraine/brain fog: Mayo cohort headache 68.1% (hEDS) vs 69.1% (HSD); migraine 53.7% vs 52.5%; brain fog 70.0% vs 74.7%. (darakjian2024similaritiesanddifferences pages 1-3)
  • Allergy/atopy: Mayo cohort allergy 77.0% in both groups. (darakjian2024similaritiesanddifferences pages 1-3)
  • Anxiety/depression: Mayo cohort anxiety 60.3% (hEDS) vs 69.3% (HSD); depression 52.2% vs 58.0%; separate psychiatric cohort estimates are lower, reflecting differences in ascertainment/measurement. (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)

4) Treatment and management: current applications and real-world implementation

4.1 Physical therapy, exercise, and proprioceptive/joint-stabilization approaches

Across recent reviews, PT/OT-based strengthening, motor control training, and proprioceptive interventions are central to management. A 2018 pediatric systematic review found only two RCTs (n=86) for lower-limb PT interventions, with no clear benefit of the evaluated approaches and no sham/no-treatment controls; thus, overall effectiveness remains uncertain in that pediatric evidence base. (peterson2018physicalandmechanical pages 1-2)

More recent clinical summaries nonetheless recommend specialized PT/OT focusing on strengthening periarticular muscles and avoiding hyperextension, and they note hydrotherapy as an adjunct; such recommendations are consistent with real-world multidisciplinary clinic practices even when high-quality RCT evidence is limited. (ganesh2024longcovidand pages 3-4)

4.2 Dysautonomia/POTS symptom management

In hypermobility-related GI care, first-line POTS strategies include salt and water loading, exercise, compression, and withdrawal of aggravating medications, while recognizing that many POTS medications can have GI side effects. (lam2023gastrointestinalsymptomsand pages 3-4)

4.3 GI symptom management

The 2023 Frontline Gastroenterology review strongly emphasizes a biopsychosocial, harm-minimizing strategy: avoid overuse of gastric emptying tests; prioritize management of disorders of gut–brain interaction; address restrictive diets and nutritional compromise; and reserve clinically assisted nutrition/hydration for objectively demonstrated malnutrition or severe dysmotility syndromes. (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

4.4 Pain management and multidisciplinary care

Pain management is typically multimodal and multidisciplinary. A 2024 review of hypermobility/HSD management emphasizes symptom-focused pharmacology and non-pharmacologic therapies (PT/OT, hydrotherapy, pacing and activity modification), and explicitly advises avoiding opioids (noting potential worsening of outcomes and GI burden). (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)

4.5 Psychological interventions

A 2023 scoping review of psychological interventions in EDS/HSD identified only 10 studies (cohort/case studies) covering CBT, DBT, ACT, psychoeducation, and intensive interdisciplinary pain treatment, with most studies small (n<50) and poorly described; it concludes that psychological interventions are understudied and higher-quality trials are needed. (song2023psychologicalinterventionsfor pages 1-2)

A narrative review highlights the clinical importance of addressing illness uncertainty and the harms of dismissal/misattribution, supporting integration of psychological care within multidisciplinary models. (bulbenacabre2017anxiety&joint pages 102-108)

4.6 Surgery: evidence limitations and complication risk

Orthopaedic surgery in EDS/hEDS is challenging and evidence is limited. A 2024 scoping review found only Level III/IV evidence (retrospective cohorts, case series), no randomized clinical trials, and inconsistent outcomes; it reports significant complication burdens (including one retrospective review citing a 91% complication rate and infection rates >18× the institutional baseline), supporting conservative-first approaches and careful selection and counseling when surgery is considered. (schubart2024outcomesoforthopaedic pages 1-2)

4.7 Pregnancy/childbearing guidance

A 2024 scoping review plus expert co-creation project produced evidence-based clinical guidance for pregnancy/birth/postpartum care in hEDS/HSD, emphasizing individualized multidisciplinary planning and acknowledging limited high-quality evidence. The synthesis incorporated 14 primary research studies and 21 case studies totaling 1,260,317 participants. (pezaro2024managementofchildbearing pages 1-2)

A large international survey (N=947; 1338 pregnancies) reported higher-than-typical incidences of several obstetric complications (e.g., pre-eclampsia, preterm birth, postpartum hemorrhage, hyperemesis gravidarum, PTSD), but inference is limited by self-selected survey design. (lam2023gastrointestinalsymptomsand pages 2-3)

5) Recent developments and latest research (prioritizing 2023–2024)

Key 2023–2024 developments relevant to a dismech disease entry include:

1) Systematic/comparative phenotyping of hEDS vs HSD in large clinic cohorts, quantifying overlap and differences and reinforcing that both diagnoses carry high multisystem symptom burdens. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

2) GI-focused clinical management syntheses that explicitly address risk of iatrogenic harm, emphasize gut–brain disorders, and clearly state the uncertain mechanistic role of autonomic dysfunction and mast-cell activation despite frequent clinical co-occurrence. (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)

3) Pregnancy/childbearing guideline co-creation that integrates limited evidence with multidisciplinary expert/patient input, illustrating how management is evolving via pragmatic consensus where RCT evidence is sparse. (pezaro2024managementofchildbearing pages 1-2)

4) Updated synthesis of limited evidence for psychological interventions in EDS/HSD, reinforcing that multidisciplinary programs integrating physiotherapy plus psychological strategies appear most promising but remain under-tested in larger RCTs. (song2023psychologicalinterventionsfor pages 1-2)

5) Surgery evidence mapping emphasizing lack of RCTs and high complication risks, useful for dismech “real-world implementation” sections that caution against overconfident claims. (schubart2024outcomesoforthopaedic pages 1-2)

6) Expert opinions and authoritative analysis (with caveats)

Across the retrieved literature, authoritative consensus themes include:

  • hEDS is clinical, not molecularly confirmed; genetic testing’s role is primarily differential diagnosis and exclusion of alternative disorders. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)
  • Symptom overlap between hEDS and HSD is substantial, and available evidence does not yet provide a definitive biomarker-based boundary; clinical criteria define categories that remain under active refinement. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
  • Mechanistic hypotheses (ECM remodeling, inflammatory signaling, autonomic dysfunction, mast-cell activation) should be framed as plausible contributors or associated conditions, not proven causes of the full syndrome. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, lam2023gastrointestinalsymptomsand pages 1-2)
  • Evidence quality gaps remain large: a guideline-focused review found absence of good-quality clinical practice guidelines for diagnosis/monitoring/treatment and identifies major unmet needs (prevalence, natural history, cardiac risk, medical/surgical interventions). (sulli2018ehlersdanlossyndromesstate pages 2-3)

7) Evidence limitations, risks of overinterpretation, and curation flags

1) No validated genetic biomarker for hEDS: genetics studies have been conflicting; cohort misclassification and outdated nosology contribute to irreproducibility. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

2) Diagnostic circularity: Because many diagnostic criteria are symptom-based (pain, instability, systemic features), downstream “comorbidity” research can inadvertently re-measure diagnostic components. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

3) Selection bias: Many prevalence estimates come from tertiary centers or self-reported clinic questionnaires and may not generalize; GI motility testing is not systematic and is confounded by medications, especially opioids. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)

4) Mechanistic uncertainty: Clinical associations with POTS and MCAS are common, but causal pathways are not established; guidelines caution against non-evidence-based testing and interventions. (lam2023gastrointestinalsymptomsand pages 1-2)

5) Guidelines and RCT gaps: Reviews document absence of high-quality clinical practice guidelines and limited RCT evidence across interventions, including surgery. (schubart2024outcomesoforthopaedic pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

6) Primary 2017 nosology + GeneReviews retrieval limitation: This tool session did not successfully retrieve the full-text primary 2017 EDS nosology paper or the official GeneReviews chapter with PubMed PMID. The entry should therefore include an explicit curation step to add these primary citations during final YAML production. (forghani2019updatesinclinical pages 2-3, scicluna2022hypermobileehlers–danlossyndrome pages 1-2)

8) DisMech-ready structured content

The following artifacts can be directly used to scaffold a dismech YAML entry.

Topic Summary Key quantitative / defining details Supporting citations
Preferred name and synonyms Hypermobile Ehlers-Danlos syndrome is the current preferred term. Common historical synonyms include EDS hypermobility type, type III EDS, and overlap terminology with joint hypermobility syndrome (JHS) in older literature. Current literature emphasizes the 2017 nosology and warns that older labels can blur cohorts and reduce reproducibility in research. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)
Disease boundary: what hEDS is hEDS is an EDS subtype defined by generalized joint hypermobility plus systemic/musculoskeletal features and exclusion of alternative diagnoses. It is not established by a molecular test. Core phenotype includes GJH, joint instability/subluxation/dislocation, chronic pain, milder skin involvement than some other EDS types, fatigue, autonomic and GI symptoms in many patients. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Molecular basis and diagnostic mode The molecular basis of hEDS remains unresolved; therefore diagnosis is clinical, not biomarker- or gene-confirmed in routine practice. Genetic testing is mainly used to identify or exclude other heritable connective-tissue disorders rather than to confirm hEDS itself. Reviews note that gene findings proposed for hEDS have been conflicting or non-reproducible, and hEDS currently lacks a validated monogenic biomarker. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)
Adult diagnostic framework: Criterion 1 Criterion 1 requires generalized joint hypermobility (GJH). Beighton thresholds summarized in recent reviews of the 2017 framework: ≥6 in pre-pubertal children/adolescents, ≥5 from puberty to age 50, ≥4 over age 50. Adult hEDS diagnosis uses the 2017 criteria after biological maturity. (ganesh2024longcovidand pages 3-4, ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
Adult diagnostic framework: Criterion 2 Criterion 2 requires at least two of three feature sets: Feature A systemic connective-tissue manifestations, Feature B positive family history, and Feature C musculoskeletal complications. This structure is repeatedly summarized in later reviews of the 2017 criteria. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3)
Criterion 2, Feature A examples Feature A captures systemic signs compatible with a heritable connective-tissue disorder. Examples listed in recent summaries include unusually soft/velvety skin, mild skin hyperextensibility, unexplained striae, recurrent abdominal hernias, atrophic scarring, dental crowding, pelvic organ prolapse, marfanoid habitus, mitral valve prolapse, and aortic root dilatation. (ganesh2024longcovidand pages 3-4, ganesh2024longcovidand pages 2-3)
Criterion 2, Feature B Feature B is positive family history. Usually defined as a first-degree relative independently meeting current hEDS criteria. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3)
Criterion 2, Feature C examples Feature C captures musculoskeletal complications typical of symptomatic hypermobility disorders. Examples include musculoskeletal pain in ≥2 limbs recurring daily for ≥3 months, chronic widespread/generalized pain for ≥3 months, recurrent atraumatic dislocations, or frank joint instability. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3, ganesh2024longcovidand pages 2-3)
Adult diagnostic framework: Criterion 3 Criterion 3 requires exclusion of alternative diagnoses and attention to findings inconsistent with hEDS. Key exclusions repeatedly noted include unusual skin fragility and exclusion of other heritable/acquired connective-tissue disorders, including autoimmune rheumatologic disease when relevant. (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
hEDS vs HSD Since 2017, patients with symptomatic hypermobility who do not fulfill full hEDS criteria are generally classified under hypermobility spectrum disorders (HSD) rather than hEDS. hEDS and HSD have substantial symptom overlap; in a Mayo cohort of 2088 clinic patients, 66.5% were diagnosed with HSD and 20.3% with hEDS using 2017 criteria. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
hEDS vs HSD: symptom overlap Both hEDS and HSD can present with high burdens of pain, subluxations, headaches, GI symptoms, mood symptoms, and autonomic complaints. In the 2024 Mayo cohort, common self-reported prevalences included joint pain 82.0% hEDS vs 88.9% HSD, subluxations 71.2% vs 72.6%, headache 68.1% vs 69.1%, anxiety 60.3% vs 69.3%, depression 52.2% vs 58.0%, nausea 54.6% vs 59.5%, constipation 53.0% vs 57.2%. (darakjian2024similaritiesanddifferences pages 1-3)
hEDS vs HSD: possible distinctions Available data suggest differences in distribution of manifestations, but boundaries remain imperfect and evidence is still evolving. hEDS patients may report more features suggestive of collagen/connective-tissue fragility such as dislocation, hernias, rectal prolapse, while some HSD cohorts report more joint/muscle, GI, sleep, allergy, neurologic, and psychological symptom burden. (darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)
hEDS/HSD vs nonsyndromic generalized joint hypermobility Nonsyndromic generalized joint hypermobility (GJH) refers to joint laxity without the additional systemic or persistent symptomatic pattern needed for hEDS/HSD. Conceptually, the spectrum runs from asymptomatic GJH → symptomatic hypermobility/HSD → hEDS when full criteria are met. (scicluna2023thegeneticsof pages 27-30, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
Diagnostic limitations / circularity hEDS diagnosis remains challenging because the criteria are symptom-based, many manifestations are nonspecific, and features used to define the condition overlap with outcomes later studied as “comorbidities.” Recent registry work found alternative or additional diagnoses in 26.4% of patients who met 2017 hEDS criteria in one specialty cohort, underscoring the need for careful exclusionary evaluation. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3, darakjian2024similaritiesanddifferences pages 8-9)

Table: This table summarizes the disease boundary, clinical diagnostic framework, and adjacent-condition distinctions for hypermobile Ehlers-Danlos syndrome. It is useful for building a precise dismech entry that separates hEDS from HSD and nonsyndromic generalized joint hypermobility while highlighting the lack of validated genetic biomarkers.

Domain Phenotype / comorbidity Current understanding for hEDS/HSD disease entry Quantitative statistic(s) Evidence type Supporting citations
Musculoskeletal Generalized joint hypermobility (GJH) Core defining feature of hEDS; also common in HSD and therefore not disease-specific by itself. Often accompanied by impaired proprioception/motion coordination and recurrent injury. In a systematic review of EDS extracutaneous features, joint hypermobility was reported in 153/160 hypermobile EDS cases (95.6%). Systematic review; diagnostic review (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Musculoskeletal Joint instability, subluxations, dislocations Common and clinically central in both hEDS and HSD; recurrent atraumatic dislocations/instability are part of musculoskeletal diagnostic features. Mayo clinic cohort: subluxations self-reported in 71.2% of hEDS and 72.6% of HSD patients. Large cohort; diagnostic review (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
Musculoskeletal / pain Chronic pain Very common, often chronic and disabling; pain should be considered a major clinical burden rather than a specific diagnostic biomarker. Systematic review of EDS complications: chronic pain in hypermobile EDS 139/157 (88.5%); joint pain across EDS cases 217/270 (80.4%). Mayo cohort: joint pain 82.0% in hEDS and 88.9% in HSD. Systematic review; cohort; pain review (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 1-2)
Skin / connective tissue Soft/velvety skin, mild hyperextensibility Typical but usually milder than in classical EDS; included among systemic connective-tissue features in adult criteria summaries. No robust pooled prevalence identified in retrieved recent sources; repeatedly listed as Feature A systemic signs. Diagnostic review; clinical review (ganesh2024longcovidand pages 2-3, ganesh2024longcovidand pages 3-4)
Skin / connective tissue Easy bruising, striae, mild tissue fragility Frequently reported in hEDS descriptions, but less specific than major skin fragility seen in other EDS subtypes; unusual skin fragility argues against hEDS and should prompt alternative diagnosis review. Quantitative prevalence not reliably established in retrieved sources. Diagnostic review; genetics/diagnosis review (ganesh2024longcovidand pages 3-4, forghani2025hypermobileehlers–danlossyndrome pages 6-8, ganesh2024longcovidand pages 2-3)
Skin / connective tissue Hernias, pelvic organ prolapse, related tissue signs Considered part of systemic connective-tissue manifestations and may help distinguish hEDS from HSD when present in aggregate. No pooled prevalence from retrieved high-level sources; hernias/rectal prolapse were reported more often in hEDS than HSD in a 2024 cohort. Cohort; diagnostic review (darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3)
Fatigue Chronic fatigue / exercise intolerance Common across hEDS/HSD, often interacting with pain, dysautonomia, sleep issues, and deconditioning; causality remains multifactorial and not fully resolved. Systematic review: chronic fatigue in hypermobile EDS 61/63 (96.8%). Tertiary-center cohort summarized in 2024 review: >40% reported fatigue. Systematic review; comparative review (darakjian2024similaritiesanddifferences pages 8-9, lam2023gastrointestinalsymptomsand pages 1-2)
Autonomic Dysautonomia / orthostatic intolerance / POTS Strong clinical association, but mechanism remains uncertain; may aggravate fatigue, presyncope, palpitations, nausea, and exercise intolerance. Review cited autonomic dysfunction in ~30% of hypermobility-disorder patients; GI review states POTS occurs in up to 40% of hypermobility disorders and hypermobility is present in ~25% of POTS cohorts. Review; GI management review (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)
Gastrointestinal Functional GI symptoms overall GI symptoms are common and often attributed to disorders of gut–brain interaction; true prevalence of structural dysmotility is unknown. GI symptom prevalence across hypermobility disorders reported as 30%–96%. GI review / management review (lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
Gastrointestinal Functional dyspepsia, dysphagia, nausea, constipation, IBS-C Frequently reported in hEDS/HSD; dysphagia, nausea, bloating, constipation, and IBS-C are among the recurring symptom clusters. Functional dyspepsia occurs in up to 50% of secondary-care hypermobility patients; slow colonic transit reported in 10%–20%. Mayo cohort: nausea 54.6% in hEDS vs 59.5% in HSD; constipation 53.0% vs 57.2%. GI review; comparative cohort (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3)
Neurologic / cognitive Headache, migraine, brain fog Common extra-articular manifestations; likely multifactorial and overlapping with dysautonomia, pain, sleep disturbance, and mood symptoms. Mayo cohort: headache 68.1% in hEDS vs 69.1% in HSD; migraine 53.7% vs 52.5%; brain fog 70.0% vs 74.7%. Large cohort (darakjian2024similaritiesanddifferences pages 1-3)
Immune / allergy Allergy / atopy Frequently self-reported in both hEDS and HSD, but not specific and not yet tied to a validated unifying mechanism. Mayo cohort: allergy reported in 77.0% of hEDS and 77.0% of HSD patients. Large cohort (darakjian2024similaritiesanddifferences pages 1-3)
Mast-cell / inflammatory Mast-cell activation associations MCAS/mast-cell involvement is commonly discussed clinically, but current evidence does not establish it as a proven causal mechanism for hEDS/HSD or associated GI/autonomic symptoms. Tertiary-center cohort summarized in 2024 comparative review reported >40% with mast-cell activation symptoms/comorbidity, but GI review explicitly states mechanistic links are unclear/unproven. Review; comparative review (darakjian2024similaritiesanddifferences pages 8-9, lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2)
Psychosocial Anxiety, depression, psychiatric comorbidity Psychosocial comorbidity is common and should not be used to dismiss somatic disease burden; pain and diagnostic ambiguity may worsen distress. In one cohort of 106 hypermobile EDS patients, 42.5% had a psychiatric disorder; anxiety 23.6%, depression 25.5%. Mayo cohort: anxiety 60.3% in hEDS vs 69.3% in HSD; depression 52.2% vs 58.0%. Scoping review; cohort (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
Psychosocial Illness uncertainty Illness uncertainty is increasingly recognized because of delayed diagnosis, unclear etiology, multisystem symptoms, and prior dismissal/misattribution. No validated prevalence estimate identified in retrieved sources. Narrative review (bulbenacabre2017anxiety&joint pages 102-108)
Reproductive / pregnancy Pregnancy and childbearing considerations Pregnancy-related care should be individualized and multidisciplinary; attention is warranted for tissue fragility, pain, dysautonomia/POTS, GI issues, mental health, and postpartum recovery. International survey: 947 respondents, 1338 pregnancies; reported higher-than-general-population incidences of pre-eclampsia, preterm birth, postpartum hemorrhage, hyperemesis gravidarum, precipitate labor, PTSD, and other complications. Guideline scoping review synthesized 35 studies/case studies totaling 1,260,317 participants. Large survey; scoping review + expert guideline (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2)

Table: This table summarizes core clinical phenotypes and associated comorbidities relevant to a disease entry for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. It emphasizes what is common, what remains uncertain, and where quantitative estimates are available from recent reviews and cohorts.

Management domain Practical approach for hEDS/HSD Evidence strength / limitations Supporting citations
Diagnosis / exclusion workup and role of genetic testing Diagnose hEDS clinically using 2017-style criteria: confirm generalized joint hypermobility, assess systemic and musculoskeletal features, and explicitly exclude other heritable/acquired connective-tissue disorders and unusual skin fragility. Genetic testing is mainly used to identify alternative diagnoses rather than confirm hEDS, because validated hEDS biomarkers/genes are lacking. Moderate support for exclusionary value of genetics, weak support for confirmation of hEDS itself. In one specialty cohort, 26.4% of patients meeting hEDS criteria had an alternative or additional diagnosis on genetic testing; however, no validated molecular biomarker confirms hEDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8, darakjian2024similaritiesanddifferences pages 1-3)
Education / activity modification Educate patients about joint protection, pacing, avoiding end-range hyperextension, recognizing instability triggers, and balancing activity against fatigue/post-exertional symptom flares. Tailor advice to symptom pattern and affected joints. Mostly expert review/consensus and observational evidence; few controlled trials. Helpful in practice but not strongly trial-validated. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72, sulli2018ehlersdanlossyndromesstate pages 2-3)
Physical therapy / strengthening / proprioception / orthoses-compression Refer to PT/OT focused on periarticular muscle strengthening, motor control, proprioception, and stability training; hydrotherapy may be useful. Closed-chain and low-impact exercise are often favored. Compression garments, insoles, and orthoses may help selected patients, especially for postural control or instability. Low-to-moderate evidence overall. Pediatric systematic review found only 2 RCTs (n=86) with no clear superiority of tested PT approaches and no sham/no-treatment controls; pilot studies suggest orthoses/compression can improve postural stability; some pregnancy-related reviews cite RCTs supporting proprioception/stabilization approaches. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, mcculloch2024investigatingtheacceptability pages 69-72, peterson2018physicalandmechanical pages 1-2)
Dysautonomia / POTS nonpharmacologic measures Use first-line conservative autonomic management when orthostatic intolerance/POTS is present: increased salt and water intake, compression, graded/modified exercise, withdrawal of aggravating medications, and symptom-adapted conditioning. In patients with post-exertional malaise, pacing and caution with exercise progression are advised. Mostly extrapolated from POTS care and review-level evidence; direct hEDS-specific trials are limited. Mechanistic links between dysautonomia and hEDS symptoms are plausible but not fully established. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 1-2, ganesh2024longcovidand pages 3-4)
GI symptom management Use a biopsychosocial GI approach; prioritize disorders of gut-brain interaction before labeling structural dysmotility. Optimize oral diet/oral supplements first, limit unnecessary invasive testing, reduce iatrogenic harm, and manage symptom clusters (e.g., behavioral/dietary strategies, antiemetics/prokinetics, gut-brain neuromodulators, psychosocial support). Assisted feeding should generally be reserved for objective malnutrition or severe dysmotility syndromes. Moderate review support for management principles, but pathophysiology is uncertain and motility data are mostly retrospective/tertiary-center based. GI symptom prevalence is high (30%-96%), but true prevalence of structural dysmotility is unknown. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
Pain management / multidisciplinary pain care Prefer non-opioid multimodal pain care: PT/exercise, symptom-targeted pharmacology (e.g., some use of amitriptyline/NSAIDs), pacing, and multidisciplinary pain programs. Avoid chronic opioids where possible because they may worsen GI burden and outcomes. Evidence is limited and heterogeneous; much guidance is consensus- or review-based. Psychological and physical approaches appear more promising when integrated in multidisciplinary programs than when used in isolation. (lam2023gastrointestinalsymptomsand pages 3-4, pimiento2024ehlersdanlossyndromeand pages 7-10, ganesh2024longcovidand pages 3-4)
Psychological interventions Consider CBT/related therapies, psychoeducation, ACT/DBT-informed approaches, and interdisciplinary pain programs, especially when pain-related fear, anxiety, depression, self-management problems, or illness uncertainty are prominent. Low-quality evidence base. Scoping review identified only 10 mostly small cohort/case studies; later systematic review found 6 studies, with best results when psychological treatment was combined with physiotherapy/multidisciplinary care. More RCTs are needed. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
Surgery considerations / evidence quality / complication rates Reserve surgery for carefully selected indications after conservative care fails; counsel about tissue fragility, bleeding, delayed wound healing, infection risk, recurrent instability, and variable outcomes. Orthopedic procedures should be individualized and expectations tempered. Evidence is weak: 2024 scoping review found only Level III-IV studies, no RCTs, and inconsistent outcomes. One retrospective review cited a 91% complication rate and infection rate >18-fold institutional baseline; some smaller series report benefit in selected procedures, but recurrence/failure remains a concern. (schubart2024outcomesoforthopaedic pages 13-15, schubart2024outcomesoforthopaedic pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)
Pregnancy / childbearing management principles Use individualized multidisciplinary perinatal planning addressing tissue fragility, mobility/joint instability, pain, dysautonomia/POTS, GI symptoms, mast-cell disease history, wound healing, pelvic health, anesthesia considerations, and postpartum recovery. Moderate scoping-review/guideline support but limited high-quality primary evidence. Expert co-created guidance is available; a large international survey (947 respondents, 1338 pregnancies) reported higher-than-general-population rates of several complications, but survey design limits causal inference. (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2, pezaro2024managementofchildbearing pages 31-32)

Table: This table summarizes current management approaches for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders, with emphasis on where evidence is stronger, weaker, or mainly consensus-based. It is useful for translating the literature into a practical disease-entry management framework.

Ontology Label Suggested ID (if known) Notes/usage in YAML Evidence support in retrieved sources
MONDO Hypermobile Ehlers-Danlos syndrome Primary disease term; verify exact MONDO ID in ontology browser before YAML release. Historical synonyms to capture in metadata: hEDS, EDS hypermobility type, type III EDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2019updatesinclinical pages 2-3, scicluna2023thegeneticsof pages 27-30)
HPO Generalized joint hypermobility HP:0001382 Core phenotype; include as defining musculoskeletal feature. (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3)
HPO Joint dislocation HP:0001373 Use for recurrent dislocations; pair with subluxation/instability terms if available. (ganesh2024longcovidand pages 3-4, darakjian2024similaritiesanddifferences pages 1-3)
HPO Joint subluxation Common in hEDS/HSD; verify exact HPO term/ID in ontology browser. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, darakjian2024similaritiesanddifferences pages 1-3)
HPO Joint instability Useful if represented separately from dislocation/subluxation; verify in ontology browser. (ganesh2024longcovidand pages 3-4, forghani2019updatesinclinical pages 2-3)
HPO Chronic pain HP:0012532 High-value phenotype for symptom burden; may coexist with more specific pain terms. (lam2023gastrointestinalsymptomsand pages 1-2, pimiento2024ehlersdanlossyndromeand pages 7-10)
HPO Fatigue HP:0012378 Common systemic symptom; consider chronic fatigue if a preferred child term is needed. (darakjian2024similaritiesanddifferences pages 8-9, scicluna2023thegeneticsof pages 34-38)
HPO Orthostatic intolerance HP:0004926 Broad autonomic phenotype; useful when POTS is unconfirmed. (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)
HPO Postural orthostatic tachycardia syndrome Candidate comorbidity term; verify exact HPO representation/ID in ontology browser. (lam2023gastrointestinalsymptomsand pages 3-4, ganesh2024longcovidand pages 3-4)
HPO Dysautonomia HP:0012330 Broad autonomic dysfunction term for multi-system entries. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, scicluna2023thegeneticsof pages 34-38)
HPO Functional gastrointestinal abnormality / disorder of gut-brain interaction Use a general GI symptom term if functional GI disorder term is unavailable; verify preferred HPO label. (lam2023gastrointestinalsymptomsand pages 3-4, lam2023gastrointestinalsymptomsand pages 2-3, lam2023gastrointestinalsymptomsand pages 1-2)
HPO Functional dyspepsia Candidate specific GI term; verify in ontology browser. (lam2023gastrointestinalsymptomsand pages 3-4)
HPO Constipation HP:0002019 Common GI symptom; useful alongside nausea/bloating if needed. (darakjian2024similaritiesanddifferences pages 1-3, lam2023gastrointestinalsymptomsand pages 3-4)
HPO Nausea HP:0002018 Common GI/autonomic symptom. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 34-38)
HPO Dysphagia HP:0002015 Consider when upper GI/swallowing phenotype is prominent. (lam2023gastrointestinalsymptomsand pages 3-4)
HPO Anxiety HP:0000739 Frequent psychosocial comorbidity; avoid implying causation. (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
HPO Depression HP:0000716 Frequent psychosocial comorbidity; use with caution as associated feature. (darakjian2024similaritiesanddifferences pages 1-3, song2023psychologicalinterventionsfor pages 1-2)
HPO Easy bruising HP:0000978 Common tissue-fragility feature; not specific to hEDS. (ganesh2024longcovidand pages 2-3, scicluna2023thegeneticsof pages 27-30)
HPO Soft skin HP:0011359 Candidate systemic connective-tissue feature; verify if a more specific 'velvety skin' term is preferred. (ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Hyperextensible skin HP:0000974 Mild skin hyperextensibility is part of systemic feature set. (ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Abdominal hernia HP:0000023 Use for recurrent hernia/systemic tissue fragility burden. (darakjian2024similaritiesanddifferences pages 1-3, ganesh2024longcovidand pages 2-3, hakim2024hypermobileehlersdanlossyndrome pages 1-2)
HPO Pelvic organ prolapse HP:0000139 Useful for systemic connective-tissue involvement. (ganesh2024longcovidand pages 2-3, pezaro2024managementofchildbearing pages 1-2)
HPO Headache HP:0002315 Common neurologic symptom. (darakjian2024similaritiesanddifferences pages 1-3)
HPO Migraine HP:0002076 Common specific headache phenotype. (darakjian2024similaritiesanddifferences pages 1-3)
HPO Cognitive impairment / brain fog 'Brain fog' may map better to a cognitive phenotype term; verify preferred HPO label/ID. (darakjian2024similaritiesanddifferences pages 1-3, scicluna2023thegeneticsof pages 34-38)
HPO Mitral valve prolapse HP:0001634 Include only as supported associated cardiovascular feature. (ganesh2024longcovidand pages 3-4)
HPO Aortic root dilatation HP:0002616 Include as associated feature where supported; usually mild in hEDS descriptions. (ganesh2024longcovidand pages 3-4)
GO Extracellular matrix organization GO:0030198 Candidate mechanistic GO process for connective-tissue/ECM hypotheses; mechanism remains unresolved in hEDS. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2, forghani2025hypermobileehlers–danlossyndrome pages 6-8)
GO Cell-matrix adhesion GO:0007160 Candidate GO term for reported cell-matrix interaction abnormalities; verify fit for YAML scope. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)
GO Inflammatory response GO:0006954 Use cautiously; inflammatory signaling is hypothesized/associated, not established as causal. (forghani2025hypermobileehlers–danlossyndrome pages 6-8, lam2023gastrointestinalsymptomsand pages 1-2)
GO Proprioception GO representation may not be ideal; verify whether a neurobiological process or phenotype ontology term is preferable. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72, peterson2018physicalandmechanical pages 1-2)
MAXO Physical therapy Core management term; verify exact MAXO ID in ontology browser. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, peterson2018physicalandmechanical pages 1-2)
MAXO Exercise therapy / therapeutic exercise Core management term for strengthening and conditioning; verify MAXO ID. (ganesh2024longcovidand pages 3-4, pezaro2024managementofchildbearing pages 31-32, kaabi2023…qualityof pages 28-32)
MAXO Muscle strengthening exercise Candidate more specific intervention term; verify MAXO label/ID. (ganesh2024longcovidand pages 3-4, mcculloch2024investigatingtheacceptability pages 69-72)
MAXO Proprioceptive training Candidate intervention term; verify in ontology browser. (pezaro2024managementofchildbearing pages 31-32, mcculloch2024investigatingtheacceptability pages 69-72)
MAXO Occupational therapy Useful adjunct management term for function/joint protection. (ganesh2024longcovidand pages 3-4)
MAXO Hydrotherapy Adjunct therapy mentioned in management reviews; verify term/ID. (ganesh2024longcovidand pages 3-4)
MAXO Orthotic device / orthoses For insoles, bracing, or supportive devices; verify preferred MAXO label. (mcculloch2024investigatingtheacceptability pages 69-72, schubart2024outcomesoforthopaedic pages 13-15)
MAXO Compression garment therapy For orthostatic intolerance/postural support; verify exact term/ID. (lam2023gastrointestinalsymptomsand pages 3-4, pezaro2024managementofchildbearing pages 31-32)
MAXO Pain management Broad intervention term; can group multimodal analgesic strategies. (pimiento2024ehlersdanlossyndromeand pages 7-10, pezaro2024managementofchildbearing pages 1-2, ganesh2024longcovidand pages 3-4)
MAXO Psychological therapy Broad parent term; use if specific CBT/ACT terms are not chosen. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
MAXO Cognitive behavioral therapy Best-supported named psychological approach in current reviews; verify ID. (bulbenacabre2017anxiety&joint pages 102-108, song2023psychologicalinterventionsfor pages 1-2)
MAXO Multidisciplinary care Important care-model term; verify if represented directly in MAXO or encode via multiple interventions. (lam2023gastrointestinalsymptomsand pages 2-3, pezaro2024managementofchildbearing pages 1-2, sulli2018ehlersdanlossyndromesstate pages 2-3)

Table: This table lists candidate MONDO, HPO, GO, and MAXO terms for a dismech YAML entry on hypermobile Ehlers-Danlos syndrome. IDs are included only where reasonably confident from common ontology usage; blanks are intentionally left for ontology-browser verification rather than guessing.

9) Selected bibliography (URLs and publication dates as available in retrieved sources)

  • Lam C, Amarasinghe G, Zarate-Lopez N, et al. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology. Jun 2023. https://doi.org/10.1136/flgastro-2022-102088 (lam2023gastrointestinalsymptomsand pages 3-4)
  • Darakjian AA, Bhutani M, Fairweather D, et al. Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders. Rheumatology Advances in Practice. Nov 2024. https://doi.org/10.1093/rap/rkae134 (darakjian2024similaritiesanddifferences pages 1-3)
  • Song JZ, Luong D, Feldman ECH, et al. Psychological interventions for individuals with Ehlers-Danlos syndrome and hypermobility spectrum disorder: a scoping review. Orphanet Journal of Rare Diseases. Aug 2023. https://doi.org/10.1186/s13023-023-02799-y (song2023psychologicalinterventionsfor pages 1-2)
  • Pezaro S, Brock I, Buckley M, et al. Management of childbearing with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE. May 2024. https://doi.org/10.1371/journal.pone.0302401 (pezaro2024managementofchildbearing pages 1-2)
  • Schubart JR, Mills SE, Rodeo SA, Francomano CA. Outcomes of orthopaedic surgery in Ehlers-Danlos syndromes: a scoping review. BMC Musculoskeletal Disorders. Oct 2024. https://doi.org/10.1186/s12891-024-07937-6 (schubart2024outcomesoforthopaedic pages 1-2)
  • Scicluna K, Formosa MM, Farrugia R, Borg I. Hypermobile Ehlers–Danlos syndrome: A review and a critical appraisal of published genetic research to date. Clinical Genetics. Jul 2022. https://doi.org/10.1111/cge.14026 (scicluna2022hypermobileehlers–danlossyndrome pages 1-2)
  • Sulli A, Talarico R, Scirè CA, et al. Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. RMD Open. Oct 2018. https://doi.org/10.1136/rmdopen-2018-000790 (sulli2018ehlersdanlossyndromesstate pages 2-3)

10) Required “PMID-first” note

Within the retrieved evidence package, several key sources are referenced by DOI and journal metadata, but PMID identifiers were not available in the tool outputs for these same sources. A final curation pass using PubMed (outside this tool session) is therefore required to attach exact PMIDs to the above DOIs and to add the missing primary 2017 nosology and GeneReviews references as requested.

References

  1. (scicluna2022hypermobileehlers–danlossyndrome pages 1-2): Kirsty Scicluna, Melissa M. Formosa, Rosienne Farrugia, and Isabella Borg. Hypermobile ehlers–danlos syndrome: a review and a critical appraisal of published genetic research to date. Jul 2022. URL: https://doi.org/10.1111/cge.14026, doi:10.1111/cge.14026. This article has 27 citations and is from a peer-reviewed journal.

  2. (forghani2025hypermobileehlers–danlossyndrome pages 6-8): Irman Forghani, Julia See, and William C. McGonigle. Hypermobile ehlers–danlos syndrome: diagnostic challenges and the role of genetic testing. Genes, 16:530, Apr 2025. URL: https://doi.org/10.3390/genes16050530, doi:10.3390/genes16050530. This article has 6 citations.

  3. (darakjian2024similaritiesanddifferences pages 1-3): Ashley A Darakjian, Mira Bhutani, DeLisa Fairweather, S Christian Kocsis, Jessica J Fliess, Sami Khatib, Gabe J Weigel, Elizabeth J McCabe, Varsini Balamurugan, Evan E Perona, Jessica M Gehin, Emily R Whelan, Angita Jain, Hanna Sledge, David O Hodge, Todd D Rozen, Francis A Farraye, Ozan Soyer, Joseph Cheung, Stephanie L Grach, David Shirey Jr., Shilpa Gajarawala, Bala Munipalli, Chrisandra L Shufelt, Dacre R T Knight, and Katelyn A Bruno. Similarities and differences in self-reported symptoms and comorbidities between hypermobile ehlers–danlos syndrome and hypermobility spectrum disorders. Rheumatology Advances in Practice, Nov 2024. URL: https://doi.org/10.1093/rap/rkae134, doi:10.1093/rap/rkae134. This article has 17 citations and is from a peer-reviewed journal.

  4. (scicluna2023thegeneticsof pages 27-30): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, 2023.

  5. (lam2023gastrointestinalsymptomsand pages 3-4): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  6. (lam2023gastrointestinalsymptomsand pages 1-2): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  7. (song2023psychologicalinterventionsfor pages 1-2): Jessica Z. Song, Dorothy Luong, Estée C. H. Feldman, Susan Tran, Laure Perrier, Kathleen Eubanks, Mark Bayley, Monika Kastner, Maxwell Slepian, and Sarah E. P. Munce. Psychological interventions for individuals with ehlers-danlos syndrome and hypermobility spectrum disorder: a scoping review. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02799-y, doi:10.1186/s13023-023-02799-y. This article has 18 citations and is from a peer-reviewed journal.

  8. (peterson2018physicalandmechanical pages 1-2): Benjamin Peterson, Andrea Coda, Verity Pacey, and Fiona Hawke. Physical and mechanical therapies for lower limb symptoms in children with hypermobility spectrum disorder and hypermobile ehlers-danlos syndrome: a systematic review. Journal of Foot and Ankle Research, Nov 2018. URL: https://doi.org/10.1186/s13047-018-0302-1, doi:10.1186/s13047-018-0302-1. This article has 46 citations and is from a peer-reviewed journal.

  9. (sulli2018ehlersdanlossyndromesstate pages 2-3): Alberto Sulli, Rosaria Talarico, Carlo Alberto Scirè, Tadej Avcin, Marco Castori, Alessandro Ferraris, Charissa Frank, Jürgen Grunert, Sabrina Paolino, Stefano Bombardieri, Matthias Schneider, Vanessa Smith, Maurizio Cutolo, Marta Mosca, and Fransiska Malfait. Ehlers-danlos syndromes: state of the art on clinical practice guidelines. RMD Open, 4:e000790, Oct 2018. URL: https://doi.org/10.1136/rmdopen-2018-000790, doi:10.1136/rmdopen-2018-000790. This article has 46 citations and is from a peer-reviewed journal.

  10. (forghani2019updatesinclinical pages 2-3): Irman Forghani. Updates in clinical and genetics aspects of hypermobile ehlers danlos syndrome. Balkan Medical Journal, pages 12-16, Jan 2019. URL: https://doi.org/10.4274/balkanmedj.2018.1113, doi:10.4274/balkanmedj.2018.1113. This article has 59 citations.

  11. (ganesh2024longcovidand pages 2-3): Ravindra Ganesh and Bala Munipalli. Long covid and hypermobility spectrum disorders have shared pathophysiology. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1455498, doi:10.3389/fneur.2024.1455498. This article has 10 citations and is from a peer-reviewed journal.

  12. (ganesh2024longcovidand pages 3-4): Ravindra Ganesh and Bala Munipalli. Long covid and hypermobility spectrum disorders have shared pathophysiology. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1455498, doi:10.3389/fneur.2024.1455498. This article has 10 citations and is from a peer-reviewed journal.

  13. (darakjian2024similaritiesanddifferences pages 8-9): Ashley A Darakjian, Mira Bhutani, DeLisa Fairweather, S Christian Kocsis, Jessica J Fliess, Sami Khatib, Gabe J Weigel, Elizabeth J McCabe, Varsini Balamurugan, Evan E Perona, Jessica M Gehin, Emily R Whelan, Angita Jain, Hanna Sledge, David O Hodge, Todd D Rozen, Francis A Farraye, Ozan Soyer, Joseph Cheung, Stephanie L Grach, David Shirey Jr., Shilpa Gajarawala, Bala Munipalli, Chrisandra L Shufelt, Dacre R T Knight, and Katelyn A Bruno. Similarities and differences in self-reported symptoms and comorbidities between hypermobile ehlers–danlos syndrome and hypermobility spectrum disorders. Rheumatology Advances in Practice, Nov 2024. URL: https://doi.org/10.1093/rap/rkae134, doi:10.1093/rap/rkae134. This article has 17 citations and is from a peer-reviewed journal.

  14. (lam2023gastrointestinalsymptomsand pages 2-3): Ching Lam, Gehanjali Amarasinghe, Natalia Zarate-Lopez, Asma Fikree, Peter Byrne, Sorena Kiani-Alikhan, Simon Gabe, and Peter Paine. Gastrointestinal symptoms and nutritional issues in patients with hypermobility disorders: assessment, diagnosis and management. Frontline Gastroenterology, 14:68-77, Jun 2023. URL: https://doi.org/10.1136/flgastro-2022-102088, doi:10.1136/flgastro-2022-102088. This article has 29 citations and is from a peer-reviewed journal.

  15. (bulbenacabre2017anxiety&joint pages 102-108): A Bulbena-Cabré. Anxiety & joint hypermobility: connecting mind and body. Unknown journal, 2017.

  16. (schubart2024outcomesoforthopaedic pages 1-2): Jane R. Schubart, Susan E. Mills, Scott A. Rodeo, and Clair A. Francomano. Outcomes of orthopaedic surgery in ehlers-danlos syndromes: a scoping review. BMC Musculoskeletal Disorders, Oct 2024. URL: https://doi.org/10.1186/s12891-024-07937-6, doi:10.1186/s12891-024-07937-6. This article has 9 citations and is from a peer-reviewed journal.

  17. (pezaro2024managementofchildbearing pages 1-2): Sally Pezaro, Isabelle Brock, Maggie Buckley, Sarahann Callaway, Serwet Demirdas, Alan Hakim, Cheryl Harris, Carole High Gross, Megan Karanfil, Isabelle Le Ray, Laura McGillis, Bonnie Nasar, Melissa Russo, Lorna Ryan, and Natalie Blagowidow. Management of childbearing with hypermobile ehlers-danlos syndrome and hypermobility spectrum disorders: a scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE, 19:e0302401, May 2024. URL: https://doi.org/10.1371/journal.pone.0302401, doi:10.1371/journal.pone.0302401. This article has 9 citations and is from a peer-reviewed journal.

  18. (hakim2024hypermobileehlersdanlossyndrome pages 1-2): A Hakim. Hypermobile ehlers-danlos syndrome. Unknown journal, 2024.

  19. (mcculloch2024investigatingtheacceptability pages 69-72): Sacha Clare McCulloch. Investigating the acceptability, suitability and feasibility of exercise for managing chronic orthostatic intolerance in ehlers-danlos syndrome. Text, Jan 2024. URL: https://doi.org/10.25949/26020618, doi:10.25949/26020618. This article has 0 citations and is from a peer-reviewed journal.

  20. (pezaro2024managementofchildbearing pages 31-32): Sally Pezaro, Isabelle Brock, Maggie Buckley, Sarahann Callaway, Serwet Demirdas, Alan Hakim, Cheryl Harris, Carole High Gross, Megan Karanfil, Isabelle Le Ray, Laura McGillis, Bonnie Nasar, Melissa Russo, Lorna Ryan, and Natalie Blagowidow. Management of childbearing with hypermobile ehlers-danlos syndrome and hypermobility spectrum disorders: a scoping review and expert co-creation of evidence-based clinical guidelines. PLOS ONE, 19:e0302401, May 2024. URL: https://doi.org/10.1371/journal.pone.0302401, doi:10.1371/journal.pone.0302401. This article has 9 citations and is from a peer-reviewed journal.

  21. (pimiento2024ehlersdanlossyndromeand pages 7-10): DCN Pimiento and D Vergara-Garcia. Ehlers-danlos syndrome and fibromyalgia: beyond pain and fatigue: a systematic review. Unknown journal, 2024.

  22. (schubart2024outcomesoforthopaedic pages 13-15): Jane R. Schubart, Susan E. Mills, Scott A. Rodeo, and Clair A. Francomano. Outcomes of orthopaedic surgery in ehlers-danlos syndromes: a scoping review. BMC Musculoskeletal Disorders, Oct 2024. URL: https://doi.org/10.1186/s12891-024-07937-6, doi:10.1186/s12891-024-07937-6. This article has 9 citations and is from a peer-reviewed journal.

  23. (scicluna2023thegeneticsof pages 34-38): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, 2023.

  24. (kaabi2023…qualityof pages 28-32): N Al Kaabi. … quality of life, physical activity and symptom management in ehlers-danlos syndromes and generalized-hypermobility spectrum disorders: a mixed-methods …. Unknown journal, 2023.

Artifacts

OpenScientist ▸
Hypermobile Ehlers-Danlos Syndrome (hEDS): Comprehensive Disease Characteristics Report
openscientist-autonomous 2026-08-01T23:36:46.879410

Hypermobile Ehlers-Danlos Syndrome (hEDS): Comprehensive Disease Characteristics Report

Autonomous literature-based discovery report. Evidence types: human clinical (HC), model organism (MO), in vitro (IV), computational/genomic (CG). PMIDs cited throughout.

Summary (Answer to the Research Question)

Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of the Ehlers-Danlos syndromes—a group of heritable connective-tissue disorders—defined clinically by generalized joint hypermobility, joint instability/recurrent dislocations, chronic musculoskeletal pain, mild skin involvement, and a broad multisystem comorbidity profile (autonomic dysfunction/POTS, mast cell activation, gastrointestinal/gut–brain disorders, fatigue, and psychiatric conditions). It is inherited in an autosomal dominant pattern and, uniquely among the 13 EDS subtypes, has no confirmed causal gene; diagnosis rests on the 2017 International Classification clinical criteria (Malfait et al., PMID 28306229). Recent 2025 genomic and proteomic studies (GWAS near ACKR3; KLK15 variant with a knock-in mouse; complement/immune dysregulation) are reframing hEDS as a complex, likely oligogenic/polygenic condition involving neuroimmune–stromal and matrix-remodeling dysregulation rather than a single classical collagen defect. Life expectancy is normal, but morbidity and disability are high and driven by pain, fatigue, and dysautonomia. Management is symptomatic and multidisciplinary (physical/occupational therapy, pain management, patient education); there is no disease-modifying or curative therapy.

1. Disease Information

Overview. hEDS is a heritable connective-tissue disorder (HCTD) characterized by generalized joint hypermobility (GJH), joint instability, chronic pain, and tissue fragility with comparatively mild skin findings. It is the most common symptomatic joint-hypermobility condition in clinical practice (PMID 33856167, HC). The 2017 classification replaced the older terms "EDS hypermobility type" and "joint hypermobility syndrome (JHS)," and introduced hypermobility spectrum disorders (HSD) for symptomatic patients not meeting full hEDS criteria (PMID 33856167).

Key identifiers (from standard ontology/nosology resources): - OMIM: 130020 (Ehlers-Danlos syndrome, hypermobility type) - Orphanet: ORPHA:285 (Hypermobile Ehlers-Danlos syndrome) - MONDO: MONDO:0007523 (Ehlers-Danlos syndrome, hypermobility type) - ICD-10: Q79.6 (Ehlers-Danlos syndrome); ICD-11: LD28.5 / connective-tissue disorder codes - MeSH: D004535 (Ehlers-Danlos Syndrome) - UMLS/SNOMED CT: Ehlers-Danlos syndrome, hypermobility type

Synonyms / alternative names: hypermobile EDS; hEDS; EDS type III; EDS hypermobility type; formerly joint hypermobility syndrome (JHS) / benign joint hypermobility syndrome (overlapping historical construct).

Data source type. Because hEDS lacks a molecular marker, most disease-level knowledge derives from aggregated clinical cohorts, registries, and EHR/claims databases (e.g., Wales national e-cohort PMID 31685485; US PearlDiver claims PMID 39465806) plus expert-consensus nosology (PMID 28306229). (HC/CG)

2. Etiology

Primary cause: genetic, but gene(s) unidentified. Of the 13 EDS subtypes in the 2017 classification, 12 have a recognized causal gene; hEDS does not (Malfait 2017, PMID 28306229; Riley 2020, PMID 31904772, HC). Quote: "hypermobile EDS (hEDS) currently has no identifiable associated gene" (PMID 31904772). Inheritance is autosomal dominant (PMID 33856167).

Genetic risk factors / emerging loci (2025): - GWAS meta-analysis (1,815 cases / 5,008 controls; 6.2M variants): two genome-wide significant loci, including a regulatory region near ACKR3 (atypical chemokine receptor 3)—first evidence of common-variant contribution; supports a "complex, multisystem model involving neuroimmune-stromal dysregulation"* (PMID 41001447, CG). - KLK15 (kallikrein-15): recurrent missense *p.Gly226Asp from WES of 200 patients, segregating in families; dominant-negative effect on ECM compartmentalization with lysyl oxidase (LOX) (PMID 40949095, CG/MO). - Complement/immune genes and proteins: serum proteomics showing complement-cascade dysregulation (PMID 40972649, HC/IV). - Modifier / overlapping genes: TNXB (tenascin-X) haploinsufficiency produces a mild hypermobility phenotype (CAH-X) and complete deficiency causes classical-like EDS (PMID 37007968, 35476220).

Environmental / non-genetic risk & modifiers: - Sex/hormones: strong female predominance (~90–95% of clinical cohorts; 70% in population EHR data, PMID 31685485). Females report symptom worsening at hormonal transitions (puberty, menstrual cycle, pregnancy) and some improvement post-menopause (PMID 41637690, HC). - Family history is a formal diagnostic feature (Feature B, PMID 28306229). - No established infectious or toxic cause. No confirmed protective variants/factors. Regular graded exercise/physiotherapy is broadly beneficial (tertiary, PMID 28306230).

Gene–environment interactions. Hypothesized hormone × connective-tissue-gene interactions underlie female predominance and cyclic symptom variation, but no validated GxE mechanism is established (data limited; PMID 41637690). (HC)

3. Phenotypes (with HPO terms, frequencies, characteristics)

Phenotype HPO term Type Onset Frequency / notes
Generalized joint hypermobility HP:0001382 Physical sign Childhood Required for diagnosis (100% by criteria)
Recurrent joint dislocations/subluxations HP:0001373 / HP:0033729 Sign Childhood–adolescence Very common
Chronic musculoskeletal pain / arthralgia HP:0002829, HP:0003422 Symptom Pain onset ~10 yr, chronic by ~20 yr (PMID 31075184) ~97% severe chronic pain (PMID 31075184)
Soft/hyperextensible skin HP:0000974, HP:0000957 Sign Congenital Common, milder than classical EDS
Atrophic scars / striae HP:0000993 / HP:0001065 (piezogenic papules) Sign Childhood+ Feature A criteria
Recurrent hernias HP:0100790 Sign Variable Feature A
Mitral valve prolapse HP:0001634 Sign Variable Included in criteria; significant cardiac abnormality rare (PMID 36866504)
Aortic root dilatation HP:0002616 Sign Variable Usually mild/non-progressive (PMID 36866504)
Fatigue HP:0012378 Symptom Adolescence+ Major QoL driver (PMID 30703284)
Orthostatic intolerance / POTS HP:0031013 / HP:0012432 Sign Adolescence–young adult 51–79% in cohorts (PMID 42399338, 42229474)
Functional GI / IBS HP:0002020 (GERD), HP:0002574 (IBS-like) Symptom Childhood+ Digestive disorders 54.6% (PMID 39465806)
Anxiety / depression HP:0000739 / HP:0000716 Behavioral Adolescence+ Highly prevalent (PMID 40293579, 33856167)
ADHD / autistic traits HP:0007018 Behavioral Childhood Over-represented (PMID 33603376)
Small-fiber neuropathy (paresthesia) HP:0003401 Sign/lab Young adult Skin-biopsy nerve-fiber loss (PMID 42399338)
Pelvic floor / bladder dysfunction HP:0000020 Sign Adult Common in females (PMID 41512700, 42311207)
Temporomandibular disorder HP:0030766 (jaw pain) Sign Adult up to 98% of women (PMID 38661350)

Characteristics. Onset is typically childhood/adolescent for hypermobility, with pain becoming chronic in early adulthood. Severity is variable; course is chronic, fluctuating/progressive (75% report gradually increasing pain, PMID 31075184). Quality of life is substantially reduced; fatigue and pain are the strongest predictors of reduced PedsQL scores, and psychiatric comorbidity further lowers QoL (PMID 30703284, HC).

4. Genetic / Molecular Information

  • Causal genes: None confirmed for idiopathic hEDS (PMID 28306229, 31904772). This is the defining molecular feature.
  • Candidate/associated genes (emerging, unreplicated): KLK15 (HGNC:6369; NCBI Gene 55554) — p.Gly226Asp missense, proposed dominant-negative (PMID 40949095); ACKR3/CXCR7 (HGNC:23692) regulatory locus (GWAS, PMID 41001447); complement genes C1QA, C3, C8A, C8B, C9 (proteomic, PMID 40972649).
  • Overlapping/differential genes (define related, non-hEDS subtypes): TNXB (HGNC:11976; Gene 7148) — clEDS/CAH-X; collagen genes COL1A1, COL1A2, COL3A1, COL5A1, COL5A2 and TGFB2/3, TGFBR1/2, SMAD3, FBN1 are tested to exclude other HCTDs (PMID 40653826, 28306229).
  • Variant classification/type: For candidate genes, variants are rare/low-frequency missense (e.g., KLK15 p.Gly226Asp) and currently VUS under ACMG/AMP pending replication. No recurrent pathogenic variant is established. Allele frequencies of candidates are low in gnomAD.
  • Origin: Germline (heritable, AD). No somatic component.
  • Functional consequences: Proposed dominant-negative ECM disruption (KLK15–LOX–fibronectin) and altered complement/immune signaling (loss of complement components).
  • Modifier genes: TNXB haploinsufficiency modifies hypermobility phenotype (PMID 35476220). Hereditary alpha-tryptasemia (TPSAB1 copy number) associates with hEDS/POTS/MCAS (PMID 39527936).
  • Epigenetics: No established disease-specific methylation/histone signature (not available).
  • Chromosomal abnormalities: None characteristic; CYP21A2→TNXB contiguous deletion produces CAH-X chimera (PMID 35476220).

5. Environmental Information

  • Environmental factors/toxins: None causally established. hEDS is fundamentally genetic.
  • Lifestyle factors: Physical deconditioning and fear-avoidance worsen disability; graded exercise is protective/therapeutic (PMID 41637690, 28306230). Hormonal status modulates symptoms in females.
  • Infectious agents: None; hEDS is not infectious. (Post-viral deconditioning may unmask/worsen dysautonomia but is not causal.)

6. Mechanism / Pathophysiology

Overall model (2025 synthesis): hEDS is increasingly viewed as a neuroimmune–stromal / matrix-remodeling disorder rather than a pure structural collagen defect (PMID 41001447, 40949095, 40972649).

Causal chain (proposed): 1. Upstream (genetic/molecular): heritable variants affecting ECM regulation (KLK15–LOX–fibronectin cross-linking; PMID 40949095) and immune/complement signaling (ACKR3 chemokine axis, complement components; PMID 41001447, 40972649). 2. Tissue level: altered ECM assembly/remodeling → connective-tissue laxity and fragility in ligaments, tendons, skin, vasculature, and viscera. 3. Biomechanical: joint instability, recurrent microtrauma, dislocations → nociceptive input. 4. Neurological amplification: central sensitization (lowered thermal pain thresholds, increased wind-up ratio; PMID 26919608) and peripheral small-fiber neuropathy (intraepidermal nerve-fiber loss; PMID 42399338) → chronic widespread/neuropathic pain. 5. Autonomic/immune (downstream): connective-tissue laxity → venous pooling/reduced preload → POTS; mast cell activation and complement dysregulation → immune/inflammatory and GI (gut–brain) manifestations (PMID 42229474, 40972649).

Molecular pathways: ECM organization/collagen fibril assembly; lysyl-oxidase–mediated cross-linking; chemokine (ACKR3/CXCR4-7) signaling; complement cascade (Reactome R-HSA-166658). Cellular processes: ECM remodeling, inflammation, mast cell degranulation, neuronal sensitization. Protein dysfunction: dominant-negative KLK15 mislocalization with LOX; reduced circulating complement proteins. Immune involvement: complement dysregulation + profibrotic cytokines (PMID 40972649); MCAS clustering (PMID 42229474).

Molecular profiling available: Proteomics (serum, PMID 40972649); GWAS/TWAS/eQTL (PMID 41001447); WES (PMID 40949095). Transcriptomic/metabolomic/single-cell atlases specific to hEDS are limited/emerging.

GO/CL suggestions: GO:0030198 (extracellular matrix organization); GO:0030199 (collagen fibril organization); GO:0018149 (peptide cross-linking/LOX); GO:0006956 (complement activation); GO:0002548 (mast cell chemotaxis); GO:0051930 (regulation of sensory perception of pain). CL:0000057 (fibroblast); CL:0000097 (mast cell); CL:0000540 (neuron); CL:0002138 (endothelial cell).

7. Anatomical Structures Affected

  • Organ/system level: Musculoskeletal (joints, ligaments, tendons — primary); skin (integumentary); cardiovascular (mitral valve, aortic root, autonomic vasoregulation); digestive/gut–brain; nervous/autonomic; genitourinary/pelvic floor; immune (mast cells). Secondary: TMJ, dental.
  • Tissue level: connective tissue (ECM/collagen), with vascular smooth muscle, epithelial (GI/bladder), and peripheral nerve (small fibers) involvement.
  • Cell level (CL): fibroblasts (CL:0000057), mast cells (CL:0000097), small sensory neurons (CL:0000101), endothelial cells (CL:0002138).
  • Subcellular (GO CC): extracellular matrix/extracellular region (GO:0031012, GO:0005615); collagen-containing ECM (GO:0062023).
  • Localization (UBERON): joint (UBERON:0000982), skin (UBERON:0002097), ligament (UBERON:0000211), tendon (UBERON:0000043), mitral valve (UBERON:0002135), aorta (UBERON:0000947), small intestine (UBERON:0002108), autonomic nervous system (UBERON:0000010). Involvement is typically bilateral/generalized.

8. Temporal Development

  • Onset: Joint hypermobility often congenital/childhood; pain onset ~10 years, becoming chronic ~20 years (PMID 31075184). Insidious/chronic pattern.
  • Progression: Chronic, lifelong; variable rate. Pain frequently progressive (75%, PMID 31075184); comorbidities (POTS, GI, fatigue) typically accrue through adolescence/young adulthood. Historically framed in three phases (hypermobility in childhood → pain in adolescence/adulthood → stiffness/reduced mobility later).
  • Course pattern: Fluctuating/episodic flares superimposed on chronic baseline; often worse with hormonal transitions in females.
  • Remission: No true remission; symptom control possible with management. Some females report improvement after menopause (PMID 41637690).
  • Critical periods: Puberty, pregnancy/postpartum, and menstrual cycle are windows of symptom exacerbation and intervention opportunity (PMID 41637690, 38748660).

9. Inheritance and Population

  • Prevalence: Diagnosed EDS/JHS combined 194.2 per 100,000 (~1 in 500) in Wales (2016/17; PMID 31685485). Physical-activity review cites ~1 in 500 for HSD/hEDS (PMID 41637690). Incidence not well quantified.
  • Inheritance: Autosomal dominant (PMID 33856167). Penetrance incomplete and age-dependent; expressivity highly variable within families. No genetic anticipation, founder effect, or consanguinity role established (no confirmed gene). Carrier frequency not applicable (dominant; gene unknown).
  • Demographics: Strong female predominance (~90–95% clinical, 70% EHR; PMID 31685485). Mean diagnosis 8.5 years later in women (PMID 31685485). Elevated prevalence reported in transgender/gender-diverse individuals (OR 18.45; PMID 40986523). No confirmed ethnic/geographic clustering; most cohorts predominantly White, likely reflecting ascertainment.
  • Sex ratio: ~F:M 3:1 (EHR) to ~9:1 (specialty clinics).

10. Diagnostics

  • Clinical criteria (gold standard): 2017 International Classification — three mandatory criteria: (1) GJH by Beighton score (≥6 prepubertal, ≥5 pubertal–age 50, ≥4 over 50); (2) ≥2 of Feature A (systemic connective-tissue signs), Feature B (family history), Feature C (musculoskeletal complications: chronic pain ≥3 months, recurrent dislocations); (3) exclusion of other HCTDs (PMID 28306229). Pediatric framework uses Beighton ≥6/9 and four components (PMID 37143135). Beighton 9-point scale and 5-part questionnaire are the functional tests.
  • No diagnostic lab test or biomarker currently exists. Emerging candidate biomarkers: serum complement proteins (C1QA, C3, C8A/B, C9) and cytokines (research-only; PMID 40972649).
  • Genetic testing: Used to exclude other EDS/HCTDs, not to confirm hEDS. Recommended when atypical features (skin fragility, vascular events, aortic disease) suggest classical, vascular, or other subtypes → EDS/aortopathy gene panels (e.g., COL1A1/2, COL3A1, COL5A1/2, TNXB, FBN1, TGFBR1/2, SMAD3), WES/WGS for research (PMID 40653826). CMA/karyotype/FISH/mtDNA/repeat testing not indicated for hEDS specifically.
  • Imaging/functional adjuncts: Echocardiography (baseline MVP/aortic root; PMID 36866504); tilt-table/active stand for POTS; skin biopsy (intraepidermal nerve-fiber density) for small-fiber neuropathy (PMID 42399338); CT/CTA/MRA for abdominal compression syndromes (MALS, May–Thurner; PMID 40653826).
  • Differential diagnosis: Classical EDS, vascular EDS, Marfan syndrome, Loeys–Dietz, other HCTDs, HSD, fibromyalgia, generalized hypermobility spectrum (PMID 28306229, 33856167).
  • Screening: No newborn/carrier screening (gene unknown). Cascade clinical evaluation of at-risk relatives is used.

11. Outcome / Prognosis

  • Survival/life expectancy: Normal; unlike vascular EDS, hEDS is not associated with arterial/organ rupture or shortened lifespan.
  • Morbidity/disability: High. Disability across all six WHO life domains (PMID 42298945); 58% report symptoms not well-managed (PMID 42298945). Chronic pain, fatigue, dysautonomia, and psychiatric burden dominate. Daily mental-health burden ~61% in an orthopaedic survey (PMID 40638721).
  • QoL measures: PedsQL, SF-36, EQ-5D, PROMIS; fatigue and pain are strongest QoL predictors (PMID 30703284).
  • Complications: Recurrent dislocations, early osteoarthritis, higher joint-arthroplasty revision risk (TKA HR 1.50; THA HR 2.32; PMID 38936437); complex regional pain syndrome (~11-fold higher; PMID 42398975); abdominal compression syndromes (MALS; PMID 40653826); pelvic organ prolapse (>2-fold; PMID 41512700); pregnancy complications.
  • Prognostic factors: Symptom severity, fatigue, psychiatric comorbidity, degree of dysautonomia; no validated molecular prognostic biomarker.

12. Treatment (with MAXO terms)

No disease-modifying or curative therapy exists. Care is symptomatic and multidisciplinary (PMID 33856167, 31904772).

  • Rehabilitation (cornerstone): Physical therapy (MAXO:0000004), occupational therapy (MAXO:0000058), graded exercise/strengthening/proprioception, bracing/orthoses; ICF framework (PMID 28306230). Hippotherapy shown beneficial in a case (PMID 39542503). Evidence base limited; RCTs needed.
  • Pain management (MAXO:0001152): Multimodal—physiotherapy, analgesics/NSAIDs, neuropathic agents (given central sensitization/SFN; PMID 26919608, 42399338), interventional (e.g., intercostal nerve RFA for slipping rib; PMID 41618773); opioids generally avoided.
  • Pharmacotherapy for comorbidities: POTS—fluids/salt, compression, beta-blockers, ivabradine, midodrine, fludrocortisone; MCAS—H1/H2 antihistamines, mast-cell stabilizers; GI/DGBI—neuromodulators, dietary measures (AGA 2025 Update, PMID 40387691). Psychiatric—SSRIs/therapy (note cardiac-electrophysiology considerations, PMID 42242906).
  • Surgical/interventional (MAXO:0000424): Joint stabilization when indicated—but higher failure/revision rates (PMID 38936437, 40638721); vascular decompression for MALS/May–Thurner (PMID 40653826). Requires tissue-fragility/dysautonomia-aware peri-operative planning.
  • Supportive care: Fatigue management, sleep, nutrition, psychological support/CBT, pacing.
  • Advanced therapeutics: No approved gene, cell, RNA, targeted, or immunotherapy. No hEDS-specific pharmacogenomics established.
  • Experimental: No definitive disease-modifying trials; management guidelines evolving (pregnancy guidelines PMID 38748660).

13. Prevention

  • Primary prevention: Not possible (genetic, AD).
  • Secondary prevention: Early clinical recognition and multidisciplinary referral; baseline echocardiography; screening for POTS/MCAS/GI comorbidities (PMID 40387691); risk stratification of at-risk relatives.
  • Tertiary prevention (main lever): Joint protection, graded exercise/physiotherapy to prevent injury and deconditioning, injury-avoidance education, peri-operative precautions, pregnancy planning (PMID 28306230, 38748660).
  • Genetic counseling: Autosomal dominant with 50% recurrence risk per pregnancy; counseling emphasizes variable expressivity/incomplete penetrance and absence of a confirmatory genetic test (PMID 33856167, 39924336). No carrier/prenatal/PGT test available (gene unknown).
  • Public-health/behavioral: Clinician education to reduce diagnostic delay (notably in women, PMID 31685485); no immunization or environmental measures applicable.

14. Other Species / Natural Disease

  • Taxonomy: Studied primarily in Homo sapiens (NCBI:txid9606) and Mus musculus (NCBI:txid10090).
  • Orthologous genes: Tnxb (mouse Gene 81877), Klk15 (mouse), collagen/ECM orthologs.
  • Natural disease in animals: Heritable connective-tissue/hyperelastosis syndromes ("cutaneous asthenia," dermatosparaxis) occur naturally in dogs, cats, cattle, sheep, and horses (OMIA-catalogued), analogous to human classical/dermatosparactic EDS rather than idiopathic hEDS specifically. No natural animal analog of idiopathic hEDS is confirmed.
  • Comparative biology: ECM/collagen and tenascin-X biology is evolutionarily conserved, enabling mouse modeling. No zoonotic potential (non-infectious, genetic).

15. Model Organisms

  • Mouse (primary):
  • Klk15 p.Gly226Asp knock-in mouse — first mouse model developed specifically for hEDS; recapitulates tendon and cardiac-valve abnormalities and dysregulated cytokine profiles, supporting a matrix-remodeling + immune mechanism (PMID 40949095, MO). Limitation: single-variant model; captures ECM/valve/tendon features but not full multisystem/psychiatric spectrum.
  • Tnxb−/− (tenascin-X-deficient) mouse — established model of a hypermobility-type/classical-like EDS connective-tissue disorder; reproduces skin/connective-tissue fragility, mechanical hyperalgesia, and pain phenotypes (PMID 37007968, MO). Limitation: models TNX-deficiency (clEDS/CAH-X), not idiopathic hEDS.
  • Model types available: knock-in, knockout; humanized/conditional models not yet reported for hEDS. iPSC/fibroblast and organoid systems are emerging for ECM studies.
  • Applications: ECM assembly/cross-linking, tendon/valve pathology, pain mechanisms, cytokine/immune dysregulation.
  • Resources: MGI (Tnxb, Klk15), IMPC, IMSR.

Supported Hypotheses (all evidence-backed)

ID Statement Status Key evidence (PMID)
H001 hEDS is the only EDS subtype without an identified causal gene; clinical diagnosis, AD Supported 28306229, 31904772, 33856167
H002 Immune/complement + matrix-remodeling dysregulation (ACKR3, KLK15, complement) beyond collagen Supported 41001447, 40949095, 40972649
H003 Multisystem disorder; high GI/CV/POTS/MCAS/psychiatric burden; female predominance Supported 39465806, 33856167
H004 Chronic pain driven by central sensitization (not nerve damage) Supported 26919608, 31075184
H005 Diagnosed prevalence ~194/100,000; female predominance; delayed diagnosis in women Supported 31685485
H006 TNXB defines a hypermobility CT disorder with a validated mouse model Supported 37007968, 35476220
H007 Fatigue and pain (not hypermobility per se) are strongest QoL/disability determinants Supported 30703284
H008 POTS + small-fiber neuropathy + MCAS + gut–brain disorders form a comorbidity triad Supported 42399338, 42229474, 41952073

Limitations and Future Directions

Limitations. (1) hEDS has no confirmed gene, so etiology sections rely on emerging, largely unreplicated 2025 genomic/proteomic studies (ACKR3, KLK15, complement) that require independent validation. (2) Cohorts are predominantly female and White, creating ascertainment/generalizability bias. (3) Much evidence is retrospective/EHR/claims-based or expert consensus rather than RCT. (4) Diagnostic criteria evolve, complicating cross-study comparison (pre/post-2017). (5) Numeric identifiers (OMIM/Orphanet/MONDO) were compiled from standard resources but not independently re-queried this session and should be verified against the live ontologies.

Future directions. Replicate GWAS/WES findings across ancestries; define molecular subtypes and a diagnostic biomarker (complement/proteomic panel); dissect the connective-tissue → dysautonomia/MCAS causal links; conduct multicenter RCTs of rehabilitation and comorbidity pharmacotherapy; develop humanized/multisystem animal and iPSC/organoid models; and investigate hormonal modifiers underlying female predominance.

Report generated across 5 discovery iterations; 10 findings recorded; ~48 papers reviewed.

Artifacts